エスシタロプラムのすべて

出版社: 先端医学社
著者:
発行日: 2016-01-25
分野: 臨床医学:内科  >  精神医学
ISBN: 9784865501391
電子書籍版: 2016-01-25 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

4,950 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,970 円(税込)

商品紹介

選択的セロトニン再取り込み阻害薬「エスシタロプラム」の基礎薬理、臨床薬理、有効性、うつ病の治療戦略の中での位置づけ、治療の実際やうつ病以外の病態への応用などを解説。うつ病に関する最近の臨床研究の成果等も掲載。

目次

  • エスシタロプラムのすべて

    ―目次―

    PART 1 うつ病と不安症の捉え方と治療への展望
     1.不安から抑うつへ,その病態からみた治療のあり方
     2.DSM-5などのクライテリアからみた不安症とうつ病
     3.うつ病診断に用いる評価尺度の実際と治療評価への応用
     4.バイオマーカーによるうつ病診療の可能性
     5.画像から読み取る不安症とうつ病の病態

    PART 2 うつ病と不安の病態生理と
         エスシタロプラムの臨床薬理をみる
     1.うつ病と不安症におけるシグナル伝達と5-HT受容体機能と選択性
     2.エスシタロプラムの薬理学的プロフィールと作用機序
     3.エスシタロプラムの薬物動態と臨床効果

    PART 3 うつ病における治療ストラテジーを考える
         ―エスシタロプラムを中心に―
     1.うつ病治療におけるエスシタロプラムのエビデンス
       ―系統的レビューの概観を中心に―
     2.うつ病ガイドラインとエスシタロプラムの評価
     3.わが国のうつ病治療におけるエスシタロプラムの実際と評価
     4.難治性うつ病の病態と要因
     5.非定型うつ病の考え方と治療とSSRIの位置づけ
     6.軽症うつ病の病態とSSRIの臨床応用
     7.身体的症状を有するうつ病へのSSRIの効果
     8.うつ病と認知症との関連から探る病態の捉え方とその治療
     9.脳卒中後うつ病に対する抗うつ薬による治療意義

    PART 4 不安症ならびに併存したうつ病へのアプローチ
     1.うつ病に併存する不安症へのエスシタロプラムの臨床応用
     2. 社交不安症とエスシタロプラム
     3.パニック症に併存するうつ病とエスシタロプラム
     4.双極性障害における不安症への対応
       ―薬物療法に焦点をあてて―
     5.心的外傷後ストレス障害と併存するうつ病とエスシタロプラム
     6.強迫症と併存するうつ病とエスシタロプラム

    PART 5 エスシタロプラムによる治療の実際をみる
     1.自殺念慮・企図が伺えるうつ病患者への
       エスシタロプラムの実際と注意点
     2.児童・思春期のうつ病治療の問題点とエスシタロプラムの適応
     3.高齢者うつ病患者に対するエスシタロプラムの使い方
     4.女性のうつ病・うつ状態患者へのエスシタロプラムの効果
     5.プライマリケアにおけるエスシタロプラムの使い方
     6.勤労者うつ病の現状と抗うつ薬治療
       ―エスシタロプラムの特性を生かして―
     7.他剤からエスシタロプラムへの切り替えのポイントと注意点
     8.社会復帰に向けたうつ病治療とエスシタロプラムの位置づけ

    PART 6 エスシタロプラムの安全性からみた臨床応用
     1.エスシタロプラムの安全性と副作用およびその対策
     2.エスシタロプラムの薬物相互作用―シンプル処方のために―

    PART 7 うつ病治療の今後とエスシタロプラムの役割
     1.エスシタロプラムのアロステリック薬としての期待
     2.エスシタロプラムのバイオマーカーに対する役割
       ―おもに脳由来神経栄養因子からの検討―
     3.サイコオンコロジーにおけるエスシタロプラムの役割

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

PART 1 うつ病と不安症の捉え方と治療への展望

P.20 掲載の参考文献
1) Gorman JM : Comorbid depression and anxiety spectrum disorders. Depress Anxiety 4 : 160-168, 1996-1997
2) 石郷岡純, 中村祐, 君田仲生ほか : うつ病と不安-不安について考える-. 臨床精神薬理 11 : 1391-1406, 2008
3) Lin CH, Wang FC, Lin SC et al : A comparison of inpatients with anxious depression to those with nonanxious depression. Psychiatry Res 220 : 855-860, 2014
4) Fava M, Rush AJ, Alpert JE et al : Difference in treatment outcome in outpatients with anxious versus nonanxious depression : a STAR*D report, Am. J Psychiatry 165 : 342-351, 2008
5) Dombrovski AY, Mulsant BH, Houck PR et al : Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affact Disord 103 : 77-82, 2007
6) Sakurai H, Uchida H, Abe T et al : Trajectories of individual symptoms in remitters versus non-remitters with depression, J Affect Disord 151 : 506-513, 2013
7) Papakostas GI, Larsen K : Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Eur Arch Psychiatry Clin Neurosci 261 : 147-156, 2011
8) Saveanu R, Etkin A, Duchemin AM et al : The international Study to Predict Optimized Treatment in Depression (iSPOT-D) : outcomes from the acute phase of antidepressant treatment. J Psychiatr Res 61 : 1-12, 2015
9) Lam RW, Parikh SV, Michalak EE et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry 27 : 142-149, 2015
10) Boulenger JP, Hermes A, Huusom AK et al : Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression : escitalopram vs paroxetine. Curr Med Res Opin 26 : 605-614, 2010
11) Olie JP, Tonnoir B, Menard F et al : A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress Anxiety 24 : 318-324, 2007
12) 大下隆司 : エスシタロプラムの抑うつおよび不安に対する効果. Depression Journal 1 : 92-95, 2013
13) Hashimoto S, Inoue T, Muraki I et al : Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats. Prog Neuropsychopharmacol Biol Psychiatry 33 : 113-117, 2009
14) 井上猛, 小山司 : 不安障害における扁桃体セロトニンの役割. 心身医学 49 : 291-297, 2009
15) Sanchez C, Reines EH, Montgomery SA : A comparative review of escitalopram, paroxetine, and sertraline : Are they all alike? Int Clin Psychopharmacol 29 : 185-196, 2014
16) Shinkai K, Yoshimura R, Ueda N et al : Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 24 : 11-17, 2004
P.26 掲載の参考文献
1) 高橋三郎, 大野裕監訳 : DSM-5 精神疾患の診断・統計マニュアル, 医学書院, 東京, 2014
2) 高橋三郎, 大野裕, 染矢俊幸訳 : DSM-IV-TR 精神疾患の分類と診断の手引 新訂版, 医学書院, 東京, 2003
3) Bogels SM, Knappe S, Clark LA : Adult separation anxiety disorder in DSM-5. Clin Psychol Rev 33 : 663-674, 2013
4) Bogels SM, Alden L, Beidel DC et al : Social anxiety disorder : questions and answers for the DSM-V. Depress Anxiety 27 : 168-189, 2010
5) 松永寿人 : DSM-5による不安の読解~その新たな構造と診断. Depression Strategy 4 : 5-8, 2014
6) 森則夫, 栗田大輔, 中里一貴 : 1 不安障害. 臨床家のためのDSM-5 虎の巻. 森則夫, 杉山登志郎, 岩田康秀編, 日本評論社, 東京, 2014, pp.86-90
7) 黒木俊英 : DSM-5におけるうつ病の位置づけ. Depression Strategy 4 : 1-3, 2014
8) Regier DA, Narrow WE, Kuhl EA et al : The conceptual development of DSM-V. Am J Psychiatry 166 : 645-650, 2009
9) 川嵜弘詔 : DSM-5を迎えて気分障害はどう変わっていくか, そして薬物療法はどうあるべきか. 臨床精神薬理 16 : 1271-1286, 2013
10) Kendler KS, Myers J, Zisook S : Does bereavement-related major depression differ from major depression associated with other stressful life events? Am J Psychiatry 165 : 1449-1455, 2008
11) Ghaemi N, 村井俊哉訳 : 現代精神医学原論, みすず書房, 東京, 2009, p242-247
12) 本村啓介, 神庭重信 : 抑うつ性障害DSM-5の動向と批判 (特集-精神科診断分類の改訂にむけて : DSM-5の動向) - (DSM-5ドラフトにおける精神障害). 臨床精神医学 41 : 565-575, 2012
13) 医学書院 : ICD改訂に向けた動向を探る. 週刊医学会新聞 第3144号, 2015 (https://www.igaku-shoin.co.jp/paperDetail.do?id=PA03144_01)
P.31 掲載の参考文献
1) 中根允文, Williams J : HAM-D構造化面接SIGH-D. 星和書店, 東京, 2004
2) 稲田俊也, 佐藤康一, 山本暢朋ほか : HAMDを使いこなす ハミルトンうつ病評価尺度 (HAMD) の解説と利用の手引き, 稲田俊也編, 星和書店, 東京, 2014
3) Zimmerman M, Posternak MA, Chelminski I : Is it time to replace the Hamilton Depression Rating Scale as the primary outcome measure in treatment studies of depression? J Clin Psychopharmacol 25 : 105-110, 2005
4) 上島国利, 樋口輝彦, 田村かおるほか : Montgomery Asberg Depression Rating Scale (MADRS) の日本語訳の作成経緯. 臨床精神薬理 6 : 341-363, 2003
5) 稲田俊也, 岩本邦弘, 高橋長秀ほか : MADRSを使いこなす 改訂第3版 SIGMAを用いたMADRS日本語版によるうつ病の臨床評価, 稲出俊也編著, じほう, 東京, 2013
6) Wade A, Friis Andersen H : The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 22 : 2101-2110, 2006
7) Henkel V, Seemuller F, Obermeier M et al : Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 115 : 439-449, 2009
8) 青葉安里, 元山英勝, 井尻章悟ほか : うつ病又はうつ状態の患者を対象とした塩酸パロキセチン水和物の健康関連QOLの検討 (第2報) -何が健康関連QOL改善に寄与したのか. 臨床精神薬理 8 : 1063-1075, 2005
9) 藤澤大介, 中川敦夫, 田島美幸ほか : 日本語版自己記入式簡易抑うつ尺度 (日本語版QIDS-SR) の開発. ストレス科学 25 : 43-52, 2010
10) 村松公美子, 上島国利 : プライマリ・ケア診療とうつ病スクリーニング評価ツール : Patient Health Questionnaire-9 日本語版「こころとからだの質問票」. 診断と治療 97 : 1465-1473, 2009
11) 島悟, 鹿野達男, 北村俊則 : 新しい抑うつ性自己評価尺度について. 精神医学 27 : 165-173, 1985
12) Nishiyama T, Ozaki N, Iwata N : Use of questionnaire infeasibility in order to detect cognitive disorders : example of the Center for Epidemiologic Studies Depression Scale in psychiatry settings. Psychiatry Clin Neurosci 63 : 23-29, 2009
13) 福田一彦, 小林重雄 : 自己評価式抑うつ性尺度の研究. 精神神経学雑誌 75 : 673-679, 1973
14) 錦織壮 : SDS (Zung) について二, 三の治験と考察. 心身医学 17 : 219-227, 1977
15) 小嶋雅代, 古川壽亮 : 日本版BDI-II手引, BDI-IIマニュアル, Beck AT, Steer RA, Brown GK著, 小嶋雅代, 古川壽亮訳著, 日本文化科学社, 東京, 2003
16) 後藤牧子, 上田展久, 吉村玲児ほか : Social Adaptation Self-evaluation Scale (SASS) 日本語版の信頼性および妥当性. 精神医学 47 : 483-489, 2005
17) 傳田健三, 藤井泰, 仲唐安哉ほか : Bruce Crawford : Children's Depression Rating Scale-Revised (CDRS-R) 日本語版の信頼性と妥当性の検討. 最新精神医学 17 : 51-58, 2012
18) 杉下守弘, 朝田隆 : 高齢者用うつ尺度短縮版-日本版 (Geriatric Depression Scale-Short Version-Japanese, GDS-S-J) の作成について. 認知神経科学 11 : 87-90, 2009
19) 岡野禎治, 村田真理子, 増地聡子ほか : 日本版エジンバラ産後うつ病調査票 (EPDS) の信頼性と妥当性. 精神科診断学 7 : 523-533, 1996
20) 田代哲男 : うつ病・うつ状態の寛解期における残遺症状と社会的機能化の障害-種種の治療法と新しい治療の試み-. 精神科治療学 30 : 739-745, 2015
P.36 掲載の参考文献
2) Ising M, Horstmann S, Kloiber S et al : Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker? Biol Psychiatry 62 : 47-54, 2007
3) Hori H, Teraishi T, Ota M et al. : Psychological coping in depressed outpatients : association with cortisol response to the combined dexamethasone/CRH test. J Affect Disord 152 : 441-447, 2014
4) 功刀浩ほか : うつ病のバイオマーカーと亜型-特に視床下部-下垂体-副腎系機能との関連について-. 臨床精神医学 42 : 991-998, 2013
5) Owens M, Herbert J, Jones PB et al : Elevated morning cortisol is a stratified population-level biomarker for major depression in boys only with high depressive symptoms. Proc Natl Acad Sci U S A 111 : 3638-3643, 2014
6) Brunoni AR, Lopes M, Fregni F : A systematic review and meta-analysis of clinical studies on major depression and BDNF levels : implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacolo 11 : 1169-1180, 2008
7) Yoshimura R, Mitoma M, Sugita A et al. : Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 31 : 1034-1037, 2007
8) Haile CN, Murrough JW, Iosifescu DV et al. : Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17 : 331-336, 2014
9) Takebayashi M, Hisaoka K, Nishida A et al : Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int J Neuropsychopharmacol 9 : 607-612, 2006
10) Takebayashi M, Hashimoto R, Hisaoka K et al : Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J Neural Transm 117 : 1119-1122, 2010
11) Domenici E, Wille DR, Tozzi F et al : Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PloS One 5 : e9166, 2010
12) Dowlati Y, Herrmann N, Swardfager W et al : A meta-analysis of cytokines in major depression. Biol Psychiatry 67 : 446-457, 2010
13) Uher R, Tansey KE, Dew T et al : An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 171 : 1278-1286, 2014
14) Yang JJ, Wang N, Yang C et al : Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 77 : e19-e20, 2014
15) Svenningsson P, Berg L, Matthews D et al : Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. Mol Psychiatry 19 : 962-964, 2014
16) Raison CL, Dantzer R, Kelley KW et al : CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha : relationship to CNS immune responses and depression. Mol Psychiatry 15 : 393-403, 2010
17) Sublette ME, Galfalvy HC, Fuchs D et al : Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun 25 : 1272-1278, 2011
18) Pandya CD, Howell KR, Pillai A : Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 46 : 214-223, 2013
19) Schroeter ML, Sacher J, Steiner J et al : Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets 4 : 1237-1248, 2013
20) Lohoff FW : Overview of the genetics of major depressive disorder. Curr Psychiatry Rep 12 : 539-546, 2010
21) Lin E, Chen PS : Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 9 : 935-946, 2008
22) McGowan PO, Sasaki A, D'Alessio AC et al : Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 12 : 342-348, 2009
23) Fuchikami M, Morinobu S, Segawa M et al : DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. Plos One 6 : e23881, 2011
24) Kim JM, Stewart R, Kang HJ et al : A longitudinal study of SLC6A4 DNA promoter methylation and poststroke depression. J Psychiatr Res 47 : 1222-1227, 2013
25) Guintivano J, Arad M, Gould TD et al : Antenatal prediction of postparturn depression with blood DNA methylation biomarkers. Mol Psychiatry 19 : 560-567, 2014
26) Higuchi F, Uchida S, Yamagata H et al : State-dependent changes in the expression of DNA methyltransferases in mood disorder patients. J Psychiatr Res 45 : 129. 5-1300, 2011
27) Schmidt HD, Shelton RC, Duman RS et al : Functional biomarkers of depression : diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36 : 2375-2394, 2011
28) Papakostas GI, Shelton RC, Kinrys et al : Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder : a pilot and replication study. Mol Psychiatry 166 : 1-8, 2011
P.41 掲載の参考文献
1) Greicius MD, Krasnow B, Reiss AL et al : Functional connectivity in the resting brain : a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A 100 : 253-258, 2003
2) Ferrari MC, Busatto GF, McGuire PK et al : Structural magnetic resonance imaging in anxiety disorders : an update of research findings. Rev Bras Psiquiatr 30 : 251-264, 2008
3) Szeszko PR, MacMillan S, McMeniman M et al : Amygdala volume reductions in pediatric patients with obsessive-compulsive disorder treated with paroxetine : preliminary findings. Neuropsychopharmacology 29 : 826-832, 2004
4) Atmaca M Yildirim BH, Ozdemir BH et al : Volumetric MRI assessment of brain regions in patients with refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30 : 1051-1057, 2006
5) Kempton MJ, Salvador Z, Munafo MR et al : Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 68 : 675-690, 2011
6) Bora E, Fornito A, Pantelis C et al : Gray matter abnormalities in major depressive disorder : a meta-analysis of voxel based morphometry studies. J Affect Disord 138 : 9-18, 2012
7) Nordanskog P, Larsson MR, Larsson EM et al : Hippocampal volume in relation to clinical and cognitive outcome after electroconvulsive therapy in depression. Acta Psychiatr Scand 129 : 303-311, 2014
8) Sacher J, Neumann J, Funfstuck T et al : Mapping the depressed brain : a meta-analysis of structural and functional alterations in major depressive disorder. J Affect Disord 140 : 142-148, 2012
9) Hanada H, Imanaga J, Yoshiiwa A et al : The value of ethyl cysteinate dimer single photon emission computed tomography in predicting antidepressant treatment response in patients with major depression. Int J Geriatr Psychiatry 28 : 756-765, 2013
10) Fu CH, Steiner H, Costafreda SG : Predictive neural biomarkers of clinical response in depression : a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis 52 : 75-83, 2013
11) Zhu X, Wang X, Xiao J et al : Evidence of a dissociation pattern in resting-state default mode network connectivity in first-episode, treatment-naive major depression patients. Biol Psychiatry 71 : 611-617, 2012
12) Zeng LL, Shen H, Liu L et al : Identifying major depression using whole-brain functional connectivity : a multivariate pattern analysis. Brain 135 : 1498-1507, 2012
13) Chase HW, Moses-Kolko EL, Zevallos C et al : Disrupted posterior cingulate-amygdala connectivity in postpartum depressed women as measured with resting BOLD fMRI. Soc Cogn Affect Neurosci 9 : 1069-1075, 2014
14) Okada F, Takahashi N, Tokumitsu Y : Dominance of the 'nondominant' hemisphere in depression. J Affect Disord 37 : 13-21, 1996
15) Matsuo K, Kato T, Fukuda M et al : Alteration of hemoglobin oxygenation in the frontal region in elderly depressed patients as measured by near-infrared spectroscopy. J Neuropsychiatry Clin Neurosci 12 : 465-471, 2000
16) Matsuo K, Kato N, Kato T : Decreased cerebral haemodynamic response to cognitive and physiological tasks in mood disorders as shown by near-infrared spectroscopy. Psychol Med 32 : 1029-1037, 2002
17) Matsuo K, Onodera Y, Hamamoto T et al : Hypofrontality and microvascular dysregulation in remitted late-onset depression assessed by functional near-infrared spectroscopy. Neuroimage 26 : 234-242, 2005
18) Suto T, Fukuda M, Ito M et al : Multichannel near-infrared spectroscopy in depression and schizophrenia : cognitive brain activation study. Biol Psychiatry 55 : 501-511, 2004
19) Kameyama M, Fukuda M, Yamagishi Y et al : Frontal lobe function in bipolar disorder : a multichannel near-infrared spectroscopy study. Neuroimage 29 : 172-184, 2006
20) Eschweiler GW, Wegerer C, Schlotter W et al : Left prefrontal activation predicts therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) in major depression. Psychiatry Res 99 : 161-172, 2000

PART 2 うつ病と不安の病態生理とエスシタロプラムの臨床薬理をみる

P.47 掲載の参考文献
1) Grunze H, Vieta E, Goodwin GM et al : The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders : update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14 : 154-219, 2013
2) Bandelow B, Zohar J, Hollander E et al : World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 9 : 248-312, 2008
3) Olivier B : Serotonin : a never-ending story. Eur J Pharmacol 753 : 2-18, 2015
4) Cowen PJ : Serotonin and depression : pathophysiological mechanism or marketing myth? Trends Pharmacol Sci 29 : 433-436, 2008
5) 服部功太郎, 功刀浩 : うつ病の脳脊髄液マーカー. 医学のあゆみ 244 : 502-506, 2013
6) 日本うつ病学会治療ガイドライン II. 大うつ病性障害 2012 Ver.1 (http://www.secretariat.ne.jp/jsmd/mood_disorder/img/120726.pdf)
7) 塩入俊樹, 市川直樹 : 神経伝達物質と不安のメカニズム, デュロキセチンのすべて. 先端医学社, 東京, 2014, pp22-29
8) Stahl S : ストール精神薬理学エッセンシャルズ 神経科学的基礎と応用 第4版, 仙波純一, 松浦雅人, 太田克也監訳, メディカル・サイエンス・インターナショナル, 東京, 2015, pp.421-453
9) Fakhoury M : Revisiting the Serotonin Hypothesis : implications for major depressive disorders. Mol Neurobiol 2015 [Epub ahead of print]
10) Dominguez-Lopez S, Howell R, Gobbi G : Characterization of serotonin neurotransmission in knockout mice : implications for major depression. Rev Neurosci 23 : 429-443, 2012
11) Ase AR, Reader TA, Hen R et al : Altered serotonin and dopamine metabolism in the CNS of serotonin 5-HT1A or 5-HT1B receptor knockout mice. J Neurochem 75 : 2415-2426, 2000
12) Albert PR, Vahid-Ansari F, Luckhart C : Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes : pivotal role of pre- and post-synaptic 5-HTIA receptor expression. Front Behav Neurosci 8 : 199, 2014
13) Stein DJ : 不安とうつの脳と心のメカニズム, 田島治, 荒井まゆみ訳, 星和書店, 東京, 2007, pp.35-48
14) 神庭重信, 三村將編 : 不安症群, 強迫症および関連症群, 心的外傷およびストレス因関連障害群, 解離症群, 身体症状症および関連症群 (DSM-5を読み解く-伝統的精神病理, DSM-IV, ICD-10をふまえた新時代の精神科診断), 中山書店, 東京, 2014, pp.40-55
15) Stahl SM : In : Selective serotonin reuptake inhibitors. Stahl's Essential Psychopharmacology, fourth edition, Cambridge University Press, England, 2013, pp.289-322
16) Pytliak M, Vargova V, Mechirova V et al : Serotonin receptors-from molecular biology to clinical applications. Physiol Res 60 : 15-25, 2011
17) Trivedi MH, Fava M, Wisniewski SR et al : Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354 : 1243-1252, 2006
18) Dawson LA : The discovery and development of vilazodone for the treatment of depression : a novel antidepressant or simply another SSRI? Expert Opin Drug Discov 8 : 1529-1539, 2013
19) Gibb A, Deeks ED : Vortioxetine : first global approval. Drugs 74 : 135-145, 2014
P.52 掲載の参考文献
1) Waugh J, Goa KL : Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 17 : 343-362, 2003
2) Hyttel J, Nielsen JB, Nowak G : The acute effect of sertindole on brain 5-HT2, D2 and α1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sect 89 : 61-69, 1992
3) Leonard B, Taylor D : Escitalopram--translating molecular properties into clinical benefit : reviewing the evidence in major depression. J Psychopharmacol 24 : 1143-1152, 2010
4) Owens MJ, Knight DL, Nemeroff CB : Second-generation SSRIs : human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50 : 345-350, 2001
5) Yamashita A, Singh SK, Kawate T et al : Crystal structure of a bacterial homologue of Na+/Cl- -dependent neurotransmitter transporters. Nature 437 : 215-223, 2005
6) Chen F, Larsen MB, Neubauer HA et al : Characterization of an allosteric citaloprarn-binding site at the serotonin transporter. J Neurochem 92 : 21-28, 2005
7) Chen F, Larsen MB, Sanchez C et al : The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 15 : 193-198, 2005
8) Sanchez C : The pharmacology of citalopram enantiomers : the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 99 : 91-95, 2006
9) Zhong H, Haddjeri N, Sanchez C : Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 219 : 1-13, 2012
10) Plenge P, Gether U, Rasmussen SG : Allosteric effects of R- and S-citalopram on the human 5-HT transporter : evidence for distinct high- and low-affinity binding sites. Eur J Pharmacol 567 : 1-9, 2007
11) Kasper S, Spadone C, Verpillat P et al : Onset of action of escitalopram compared with other antidepressants : results of a pooled analysis. Int Clin Psychopharmacol 21 : 105-110, 2006
12) Blier P, Bouchard C : Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Br J Pharmacol 113 : 485-495, 1994
13) Kasper S, Sacher J, Klein N et al : Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 24 : 119-125, 2009
14) Klein N, Sacher J, Geiss-Granadia T et al : Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram : an 123I ADAM SPECT study. Psychopharmacology (Berl) 191 : 333-339, 2007
P.60 掲載の参考文献
1) Stuart A Montgomery : Escitalopramの上市-「アロステリック効果 (allosteric multiplying effect) 」と呼ばれる特徴的な作用をもつSSRI. 臨床精神薬理 14 : 1283-1290, 2011
2) Rapaport MH, Bose A, Zheng H : Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 65 : 44-49, 2004
3) 持田製薬株式会社 : 医薬品インタビューフォーム レクサプロ(R) 錠10 mg, 2015年4月改訂 (第5版) (http://www.mochida.co.jp/dis/txt/pdf/lex_9.pdf)
4) 古野拓 : Escitalopramの基礎データと臨床試験成績. 臨床精神薬理 14 : 1291-1302, 2011
5) 伊豫雅臣 : Part 4 SSRIの投与法の実際. SSRIのすべて, 先端医学社, 東京, 2007, pp222-225
6) Olesen OV, Linnet K : Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59 : 298-309, 1999
7) Rochat B, Kosel M, Boss G et al : Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 56 : 15-23, 1998
8) von Moltke LL, Greenblatt DJ, Giancarlo GM et al : Escitaloprarn (S-citalopram) and its metabolites in vitro : cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 29 : 1102-1109, 2001
9) 佐藤宏宣, 平松良雄 : Escitalopram臨床薬物動態試験-単回投与および反復投与試験 (日本) -, 臨床精神薬理 14 : 839-855, 2011
10) シオノギ製薬株式会社 : サインバルタカプセル 20 mg・30 mg添付文書. 2013年3月改訂
11) 平安良雄 : Escitalopramの大うつ病性障害患者を対象とした用量反応・非劣性試験による有効性と安全性の検証-プラセボおよびparoxetineを対照とした二重盲検比較試験. 臨床精神薬理 14 : 913-923, 2011
12) 平安良雄 : Escitalopramの大うつ病性障害患者を対象とした長期投与試験. 臨床精神薬理 14 : 901-912, 2011
13) 平安良雄 : Escitalopramの高齢の大うつ病性障害患者を対象とした長期投与試験. 臨床精神薬理 14 : 913-923, 2011
14) Tao R, Rudacille M, Zhang G et al : Changes in intensity of serotonin syndrome caused by adverse interaction between monoamine oxidase inhibitors and serotonin reuptake blockers. Neuropsychopharmacology 39 : 1996-2007, 2014
15) Owens MJ, Knight DL, Nemeroff CB : Second-generation SSRIs : human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50 : 345-350, 2001
16) Areberg J, Christophersen JS, Poulsen MN et al : The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J 8 : E14-E19, 2006
17) Joffe P, Larsen FS, Pedersen V et al : Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 54 : 237-242, 1998

PART 3 うつ病における治療ストラテジーを考える - エスシタロプラムを中心に -

P.66 掲載の参考文献
1) Cipriani A, Santilli C, Furukawa TA et al : Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 15 : CD006532, 2009
2) Trkulja V : Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat Med J 51 : 61-73, 2010
3) Montgomery S, Hansen T, Kasper S : Efficacy of escitalopram compared with citalopram : a meta-analysis. Int J Neuropsychopharmacol 14 : 261-268, 2011
4) Gartlehner G, Gaynes BN Hansen RA et al : Comparative benefits and harms of second-generation antidepressants : background paper for the American College of Physicians. Ann Intern Med 149 : 734-750, 2008
5) Cipriani A, Furukawa TA, Salanti G et al : Comparative efficacy and acceptability of 12 new-generatiorl antidepressants : a multiple-treatments meta-analysis. Lancet 373 : 746-758, 2009
6) Patrick G, Combs G, Gavagan T : Initiating antidepressant therapy? Try these 2 drugs first. J Fam Pract 58 : 365-369, 2009
8) Nierenberg AA, Keefe BR, Leslie VC et al : Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60 : 221-225, 1999
9) Cho HJ, Lavretsky H, Olmstead R et al : Sleep disturbance and depression recurrence in community-dwelling older adults : a prospective study. Am J Psychiatry 165 : 1543-1550, 2008
10) Stein DJ, Lopez AG : Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Adv Ther 28 : 1021-1037, 2011
11) Hammad TA, Laughren T. Racoosin J : Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63 : 332-339, 2006
12) Bridge JA, Iyengar S, Salary CB et al : Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment : a meta-analysis of randomized controlled trials. JAMA 297 : 1683-1696, 2007
13) Carandang C, Jabbal R, Macbride A et al : A review of escitalopram and citalopram in child and adolescent depression. J Can Acad Child Adolesc Psychiatry 20 : 315-324, 2011
14) Gavin NI, Gaynes BN, Lohr KN et al : Perinatal depression : a systematic review of prevalence and incidence. Obstet Gynecol 106 : 1071-1083, 2005
15) Jimenez-Solern E, Andersen JT, Petersen M et al : SSRI use during pregnancy and risk of stillbirth and neonatal mortality. Am J Psychiatry 170 : 299-304, 2013
16) Cohen LS, Altshuler LL, Harlow BL et al : Relapse of malor depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295 : 499-507, 2006
17) Bellantuono C, Bozzi F, Orsolini L et al : The safety of escitalopram during pregnancy and breastfeeding : a comprehensive review. Hum Psychopharmacol 27 : 534-539, 2012
P.70 掲載の参考文献
1) 伊賀淳一, 大森哲郎, 小笠原一能ほか : 日本うつ病学会治療ガイドライン II, 大うつ病性障害 2012 ver.1, 2012
2) Gelenberg AJ, Freeman MP, Markowitz AC et al : Practice Guideline For The Treatment of Patients With Major Depressive Disorder Third Edition, 2010
3) Lam RW, Kennedy SH, Grigoriadis S et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 117 (Suppl 1) : S26-S43, 2009
4) Bauer M, Pfennig A, Severus E et al : WFSBP (生物学的精神医学会世界連合)版 単極性うつ病の生物学的治療ガイドライン 第I部 : 大うつ病性障害の急性期と継続期の治療 2013年改訂版, 山田和男訳. 星和書店, 東京, 2014
P.76 掲載の参考文献
2) Patrick G, Combs G, Gavagan T : Initiating antidepressant therapy? Try these 2 drugs first. J Fam Pract 58 : 365-369. 2009
3) Gartlehner G, Gaynes BN, Hansen RA et al : Ranking antidepressants. Lancet 373 : 1761, 2009
4) Ramsberg J, Asseburg C, Henriksson M : Effectiveness and cost-effectiveness of antidepressants in primary care : a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 7 : e42003, 2012
5) Kessler RC, Berglund P, Demler O et al : The epidemiology of major depressive disorder : results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 : 3095-3105, 2003
6) 塩入俊樹, 桑原秀樹 : うつ病の急性期に併存する不安障害の薬物療法. 臨床精神薬理 17 : 1085-1095, 2014
7) Boulenger JP, Hermes A, Huusom AK et al : Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression : escitalopram vs paroxetine. Curr Med Res Opin 26 : 605-614, 2010
8) Wade A, Friis Andersen H : The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 22 : 2101-2110, 2006
9) Katz MM, Meyers AL, Prakash A et al : Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull 42 : 94-107, 2009
10) Kilts CD, Wade AG, Andersen HF et al : Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 10 : 927-936, 2009
11) Kennedy SH, Andersen HF, Thase ME : Escitalopram in the treatment of major depressive disorder : a meta-analysis. Curr Med Res Opin 25 : 161-175, 2009
12) Favre P : Clinical efficacy and achievement of a complete remission in depression : increasing interest in treatment with escitalopram. Encephale 38 : 86-96, 2012
13) Gartlehner G, Hansen RA, Morgan LC et al : Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression : An Update of the 2007 Comparative Effectiveness Review. Agency for Healthcare Research and Quality : Rockville (MD, US), 2011 (http://effectivehealthcare.ahrq.gov/ehc/products/210/862/CER46_Antidepressants-Update_execsumm.pdf)
14) 宮田久嗣 : キールホルツの分類と薬理学的矛盾. 抗うつ薬の科学, 中山和彦編, 星和書店, 東京, 1995, pp.187-208
15) Ueda N, Yoshimura R, Shinkai K et al : Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 35 : 175-181, 2002
16) Shinkai K, Yoshimura R, Ueda N et al : Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 24 : 11-17, 2004
17) Bradley AJ, Lenox-Smith AJ : Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. J Psychopharmacol 27 : 740-758, 2013
18) Rosso G, Rigardetto S, Bogetto F et al : A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disord 136 : 172-176, 2012
19) Bose A, Tsai J, Li D : Early non-response in patients with severe depression : escitalopram up-titration versus switch to duloxetine. Clin Drug Investig 32 : 373-385, 2012
20) Leuchter AF, Cook IA, Marangell LB et al : Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder : results of the BRITE-MD study. Psychiatry Res 169 : 124-131, 2009
21) Uher R, Mors O, Rietschel M et al : Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression : a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry 72 : 1478-1484, 2011
22) 中林哲夫 : Escitalopramと他の抗うつ病との安全性の比較. 臨床精神薬理 14 : 1313-1322, 2011
23) Kornstein SG, Bose A, Li D et al : Escitalopram maintenance treatment for prevention of recurrent depression : a randomized, placebo-controlled trial. J Clin Psychiatry 67 : 1767-1775, 2006
P.83 掲載の参考文献
1) 井上猛, 小山司 : 難治性うつ病, 気分障害, 医学書院, 東京, 2008, pp512-533
2) American Psychiatric Association : Diagnostic and statistical manual of mental disorders : DSM-IV-TR. 4th editionl Text Revision, American Psychiatric Association, Washington, DC, 2000
3) Furukawa TA, Kitamura T, Takahashi K : Time to recovery of an inception cohort with hitherto untreated unipolar major depressive episodes. Br J Psychiatry 177 : 331-335, 2000
4) 井上猛, 小山司 : 三環系・四環系抗うつ薬に治療抵抗性うつ病の定義の妥当性に関する研究-第二選択の三環系・四環系抗うつ薬への変更は有効な治療戦略か-. 臨床精神医学 26 : 1603-1607, 1997
5) Thase ME, Rush AJ : Treatment-resistant depression. Psychopharmacology, The Fourth Generation of Progress. Raven Press, New York, 1995, pp.1081-1097
6) Rush AJ, Trivedi MH, Wisniewski SR et al : Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report. Am J Psychiatry 163 : 1905-1917, 2006
7) Souery D, Oswald P, Massat I et al : Clinical factors associated with treatment resistance in major depressive disorder : results from a European multicenter study. J Clin Psychiatry 68 : 1062-1070, 2007
8) Nanni V, Uher R, Danese A : Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression : a meta-analysis. Am J Psychiatry 169 : 141-151, 2012
9) Toda H, Inoue T, Tsunoda T et al : The structural equation analysis of childhood abuse, adult stressful life events, and temperaments in major depressive disorders and these influence on refractoriness. Neuropsychiatr Dis Treat 11 : 2079-2090, 2015
10) Tomaszewska W, Peselow ED, Barouche F et al : Antecedent life events, social supports and response to antidepressants in depressed patients. Acta Psychiatr Scand 94 : 352-357, 1996
11) Akiskal HS, Maser JD, Zeller PJ et al : Switching from 'unipolar' to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 52 : 114-123, 1995
12) Inoue T, Nakagawa S, Kitaichi Y et al : Long-term outcome of antidepressant-refractory depression : the relevance of unrecognized bipolarity. J Affect Disord 95 : 61-67, 2006
13) Li CT, Bai YM, Huang YL et al : Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder : cohort study. Br J Psychiatry 200 : 45-51, 2012
14) Daban C, Colom F, Sanchez-Moreno J et al : Clinical correlates of first-episode polarity in bipolar disorder. Compr Psychiatry 47 : 433-437, 2006
15) Yatham LN, Kennedy SH, Schaffer A et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder : update 2009. Bipolar Disord 11 : 225-255, 2009
16) Goodwin FK, Jamison KR : Manic-depressive illness : bipolar disorders and recurrent depression, 2nd ed, Oxford University Press, New York, 2007
17) 井上猛 : 大うつ病性障害の長期予後に影響を与える諸因子と新しい診断治療法. 精神保健研究 59 : 33-40, 2013
18) Inoue T, Inagaki Y, Kimura T et al : Prevalence and predictors of bipolar disorders in patients with a major depressive episode : the Japanese epidemiological trial with latest measure of bipolar disorder (JET-LMBP). J Affect Disord 174 : 535-541, 2015
19) Fiedorowicz JG, Endicott J, Leon AC et al : Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 168 : 40-48, 2011
20) Inoue T, Abekawa T, Nakagawa S et al : Long-term naturalistic follow-up of lithium augmentation : relevance to bipolarity. J Affect Disord 129 : 64-67, 2011
P.87 掲載の参考文献
1) West ED, Dally PJ : Effects of iproniazid in depressive syndromes. Br Med J 1 : 1491-1494, 1959
2) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5). APA, Washington DC, 2013
3) Thase ME : Recognition and diagnosis of atypical depression. J Clin Psychiatry 68 (Suppl 8) : 11-16, 2007
4) Parker G, Roy K, Mitchell P et al : Atypical depression : a reappraisal. Am J Psychiatry 159 : 1470-1479, 2002
5) Posternak MA, Zimmerman M : Partial validation of the atypical features subtype of major depressive disorder. Arch Gen Psychiatry 59 : 70-76, 2002
6) Henkel V, Mergl R, Coyne JC et al : Depression with atypical features in a sample of primary care outpatients : prevalence, specific characteristics and consequences. J Affect Disord 83 : 237-242, 2004
7) Novick JS, Stewart JW, Wisniewski SR et al : Clinical and demographic features of atypical depression in outpatients with major depressive disorder : preliminary findings from STAR*D. J Clin Psychiatry 66 : 1002-1011, 2005
8) Thase ME : Atypical depression : useful concept, but it's time to revise the DSM-IV criteria. Neuropsychapharmacology 34 : 2633-2641, 2009
9) Blanco C, Vesga-Lopez O, Stewart JW et al : Epidemiology of major depression with atypical features : results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry 73 : 224-232, 2012
10) Akiskal HS, Benazzi F : Atypical depression : a variant of bipolar II or a bridge between unipolar and bipolar II? J Affect Disord 84 : 209-217, 2005
11) Akiskal HS, Benazzi F : Continuous distribution of atypical depressive symptoms between major depressive and bipolar II disorders : dose-response relationship with bipolar family history. Psychopathology 41 : 39-42, 2008
13) Angst J, Gamma A, Sellaro R et al : Toward validation of atypical depression in the community : results of the Zurich cohort study. J Affect Disord 72 : 125-138, 2002
14) Matza LS, Revicki DA, Davidson JR et al : Depression with atypical features in the National Comorbidity Survey : classification, description, and consequences. Arch Gen Psychiatry 60 : 817-826, 2003
15) Koyuncu A, Ertekin E, Ertekin BA et al : Relationship between atypical depression and social anxiety disorder. Psychiatry Res 225 : 79-84, 2015
16) 広瀬徹也 : 「逃避型抑うつ」再考 [広瀬徹也, 内海健 (編) : うつ病論の現在-精密な臨床を目指して. 星和書店, 東京都, 2005, pp49-68
17) 坂元薫 : 青年期のうつ病 (特集うつの時代-うつ病を改めて理解する). 公衆衛生 72 : 359-363, 2008
18) 坂元薫 : 非定型うつ病はうつ病か? -非定型うつ病の診断と治療をめぐるControversy. 現代型うつ病の臨床. 創元社, 大阪府, 2009, pp.155-167
19) Henkel V, Mergl R, Allgaier AK et al : Treatment of depression with atypical features : a meta-analytic approach. Psychiatry Res 141 : 89-101, 2006
20) McGrath PJ, Stewart JW, Janal MN et al : A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression. Am J Psychiatry 157 : 344-350, 2000
21) Joyce PR, Mulder RT, McKenzie JM et al : Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline. Depress Anxiety 19 : 180-186, 2004
22) Stewart JW, McGrath PJ, Fava M et al : Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol 13 : 15-30, 2010
23) Uher R, Dernovsek MZ, Mors O et al : Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. J Affect Disord 132 : 112-120, 2011
P.92 掲載の参考文献
1) 日本うつ病学会気分障害の治療ガイドライン作成委員会 : 日本うつ病学会治療ガイドライン II. 大うつ病性障害 2012 Ver.1, 2012 (http://www.secretariat.ne.jp/jsmd/mood_disorder/img/120726.pdf)
2) National Institute for Health and Clinical Excellence : The Treatment and Management of Depression in Adults, 2009 (https://www.nice.org.uk/guidance/cg90/chapter/guidance)
3) American Psychiatric Association : Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd edition, American Psychiatric Association, Washington, 2010 (http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf)
4) Cole SA, Bird J : メディカルインタビュー-三つの機能モデルによるアプローチ~第2版, 飯島克巳. 佐々木雅人訳, メディカル・サイエンス・インターナショナル, 東京, 2003
5) 平島奈津子 : 精神科の臨床に「医療面接」のスキルを活かす. 臨床評価 40 : 401-405, 2013
6) 富田真幸, 渡邊衡一郎 : 気分障害に対する諸外国のガイドライン. 臨床精神薬理 16 ; 975-981, 2013
7) Ellis P, Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression. : Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 38 : 389-407, 2004
8) Bauer M, Bschor T, Pfennig A et al : World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 8 : 67-104, 2007
9) Kennedy SH, Lam RW, Parikh SV et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord 117 (Suppl) : S1-S2, 2009
10) Anderson IM, Ferrier IN, Baldwin RC et al : Evidence-based guidelines for treating depressive disorders with antidepressants : a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22 : 343-396, 2008
P.99 掲載の参考文献
1) Smith RC, Gardiner JC, Lyles JS et al : Exploration of DSM-IV criteria in primary care patients with medically unexplained symptoms. Psychosom Med 67 : 123-129, 2005
2) 更井啓介 : うつ病の身体症状. 躁うつ病の臨床と理論, 医学書院, 東京, 1990, pp.99
3) 張賢徳 : 抗うつ薬, 抗不安薬の処方の始め方, そして止め方-プライマリケア医のうつ病薬物療法-. (http://www.nikkeibp.co.jp/mentalhealth/primary-care/pdf/data.pdf)
4) Paykel ES, Ramana R, Cooper Z et al : Residual symptoms after partial remission : an important outcome in depression. Psychol Med 25 : 1171-1180, 1995
5) Greco T, Eckert G, Kroenke K : The outcome of physical symptoms with treatment of depression. J Gen Intern Med 19 : 813-818, 2004
6) Karp JF, Scott J, Houck P et al : Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry 66 : 591-597, 2005
7) 船津浩二, 川久保善宏, 安達融 : 仮面うつ病 vs. 身体表現性障害 (特集 まぎらわしい2つの病態の見分け方). 精神科 23 : 606-613, 2013
8) Lader M, Andersen HF, Baekdal T : The effect of escitalopram on sleep problems in depressed patients. Hum Psychopharmacol 20 : 349-354, 2005
9) Stein DJ, Lopez AG : Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Adv Ther 28 : 1021-1037, 2011
P.102 掲載の参考文献
1) Engedal K, Barca ML, Laks J et al : Depression in Alzheimer's disease : specificity of depressive symptoms using three different clinical criteria. Int J Geriatr Psychiatry 26 : 944-951, 2011
2) Benoit M, Dygai I, Migneco O et al : Behavioral and psychological symptoms in Alzheimer's disease. Relation between apathy and regional cerebral perfusion. Dement Geriatr Cogn Disord 10 : 511-517, 1999
3) Papka M, Rubio A, Schiffer RB et al : Lewy body disease : can we diagnose it? J Neuropsychiatry Clin Neurosci 10 : 405-412, 1998
4) Ballard C, Holmes C, McKeith I et al : Psychiatric morbidity in dementia with Lewy bodies : a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 156 : 1039-1045, 1999
5) Borroni B, Agosti C, Padovani A : Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB) : frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr 46 : 101-106, 2008
6) Cummings JL, Miller B, Hill MA et al : Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer type. Arch Neurol 44 : 389-393, 1987
7) Chakrabarty T, Sepehry AA, Jacova C et al : The prevalence of depressive symptoms in frontotemporal dementia : a meta-analysis. Dement Geriatr Cogn Disord 39 : 257-271, 2015
8) 楯林義孝 : 【高齢者のうつ病とその周辺】認知症とうつ病. 老年精神医学雑誌 19 : 414-419, 2008
9) 岡田和悟 : 【痴呆 (認知症) の前駆症状】 血管性痴呆の前駆症状. 老年精神医学雑誌 16 : 322-328, 2005
10) Shinagawa S, Ikeda M, Fukuhara R et al : Initial symptoms in frontotemporal dementia and semantic dementia compared with Alzheimer's disease. Dement Geriatr Cogn Disord 21 : 74-80, 2006
11) 馬場元 : 【認知症に対する薬物療法の課題】認知症のうつ状態に対する抗うつ薬使用の適否について. 精神科治療学 28 : 1583-1587, 2013
12) Banerjee S, Hellier J, Dewey M et al : Sertraline or mirtazapine for depression in dementia (HTA-SADD) : a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378 : 403-411, 2011
13) Nelson JC, Devanand DP : A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 59 : 577-585, 2011
14) Lyketsos CG, DelCampo L, Steinberg M et al : Treating depression in Alzheimer disease : efficacy and safety of sertraline therapy, and the benefits of depression reduction : the DIADS. Arch Gen Psychiatry 60 : 737-746, 2003
15) Nyth AL, Gottfries CG, Lyby K et al : A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 86 : 138-145, 1992
16) Mizukami K, Hatanaka K, Tanaka Y et al : Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 33 : 349-352, 2009
17) Seitz DP, Adunuri N, Gill SS et al : Antidepressants for agitation and psychosis in dementia. Cne Database Syst Rev 16 : CD008191, 2011
18) Gottfries CG, Nyth AL : Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. Ann N T Acad Sci 640 : 276-279, 1991
19) Pollock BG, Mulsant BH, Rosen J et al : A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 15 : 942-952, 2007
20) Geerlings MI, den Heijer T, Koudstaal PJ et al : History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 70 : 1258-1264, 2008
21) Dotson VM, Beydoun MA, Zonderman AB : Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 75 : 27-34, 2010
22) Byers AL, Yaffe K : Depression and risk of developing dementia. Nat Rev Neurol 7 : 323-331, 2011
23) Popp J, Schaper K, Kolsch H et al : CSF cortisol in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 30 : 498-500, 2009
24) Sapolsky RM, Krey LC, McEwen BS : The neuroendocrinology of stress and aging : the glucocorticoid cascade hypothesis. Endocr Rev 7 : 284-301, 1986
25) Baba H, Nakano Y, Maeshima H et al : Metabolism of amyloid-β protein may be affected in depression. J Clin Psychiatry 73 : 115-120, 2012
26) Sheline YI, West T, Yarasheski K et al : An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med 6 : 236re4, 2014
27) Cirrito JR, Disabato BM, Restivo JL et al : Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A 108 : 14968-14973, 2011
P.109 掲載の参考文献
1) Robinson RG : The Clinical Neuropsychiatry of Stroke, 2nd edition, Cambridge University Press, England, 2006 (木村真人監. 訳 : 脳卒中における臨床神経精神医学 第2版, 星和書店, 東京, 2013)
2) Robinson RG, Szetela B : Mood change following left hemispheric brain injury. Ann Neurol 9 : 447-453, 1981
3) Carson AJ, MacHale S, Allen K et al : Depression after stroke and lesion location : a systematic review. Lancet 356 : 122-126, 2000
4) Bhogal SK, Teasell R, Foley N et al : Lesion location and poststroke depression : systematic review of the methodological limitations in the literature. Stroke 35 : 794-802, 2004
5) Starkstein SE, Robinson RG, Price TR : Comparison of patients with and without poststroke major depression matched for size and location of lesion. Arch Gen Psychiatry 45 : 247-252, 1988
6) Parikh RM, Robinson RG, Lipsey JR et al : The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol 47 : 785-789, 1990
7) Morris PL, Robinson RG, Andrzejewski P et al : Association of depression with 10-year poststroke mortality. Am J Psychiatry 150 : 124-129, 1993
8) Kimura M, Robinson RG, Kosier JT : Treatment of cognitive impairment after poststroke depression : a double-blind treatment trial. Stroke 31 : 1482-1486, 2000
9) Chemerinski E, Robinson RG, Arndt S et al : The effect of remission of poststroke depression on activities of daily living in a double-blind randomized treatment study. J Nerv Ment Dis 189 : 421-425, 2001
10) Jorge RE, Robinson RG, Arndt S et al : Mortality and poststroke depression : a placebo-controlled trial of antidepressants. Am J Psychiatry 160 : 1823-1829, 2003
11) Camus V, Kraehenbuhl H, Preisig M et al. Geriatric depression and vascular diseases : what are the links? J Affect Disord 81 : 1-16, 2004
12) Smoller JW, Allison M, Cochrane BB et al : Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch Intern Med 169 : 2128-2139, 2009
13) Pan A, Okereke OI, Sun Q et al : Depression and incident stroke in women. Stroke 42 : 2770-2775, 2011
14) 村松公美子, 上島国利 : プライマリ・ケア診療とうつ病スクリーニング評価ツール : Patient Health Questionnare-9日本語版「こころとからだの質問票」. 診断と治療 97 : 1465-1473, 2009
15) Robinson RG, Jorge RE, Moser DJ et al : Escitalopram and problem-solving therapy for prevention of poststroke depression : a randomized controlled trial. JAMA 299 : 2391-2400, 2008
16) Jorge RE, Acion L, Moser D et al : Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 67 : 187-196, 2010
17) Salter KL, Foley NC, Zhu L et al : Prevention of poststroke depression : does prophylactic pharmacotherapy work? J Stroke Cerebrovasc Dis 22 : 1243-1251, 2013
18) Lee CH, Park JH, Yoo KY et al : Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress. Exp Neurol 229 : 450-459, 2011
19) Mnie-Filali O, Faure C, Mansari ME et al : R-citalopram prevents the neuronal adaptive changes induced by escitalopram. Neuroreport 18 : 1553-1556, 2007
20) 木村真人 : 脳卒中地域連携パスにおけるPHQ-9を用いたうつ病・うつ状態の評価と運用実績. 身体疾患を合併する精神疾患患者の診療の質の向上に資する研究-厚生労働科学研究費補助金 (障害者対策総合研究事業 (精神障害分野) 平成24-26年度総合研究報告書 研究代表者 伊藤弘人) 分担研究報告書, 2015, pp.87-101

PART 4 不安症ならびに併存したうつ病へのアプローチ

P.119 掲載の参考文献
1) Kessler RC, McGonagle KA, Zhao S et al : Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51 : 8-19, 1994
2) Gorman JM : Comorbid depression and anxiety spectrum disorders. Depress Anxiety 4 : 160-168, 1996-1997
3) Nutt DJ : Care of depressed patients with anxiety symptoms. J Clin Psychiatry 60 (Suppl 17) : 23-27, 1999
4) Mosing MA, Gordon SD, Medland SE et al : Genetic and environmental influences on the co-morbidity between depression, panic disorder, agoraphobia, and social phobia : a twin study. Depress Anxiety 26 : 1004-1011, 2009
5) van Tol MJ, van der Wee NJ, van den Heuvel OA et al : Regional brain volume in depression and anxiety disorders. Arch Gen Psychiatry 67 : 1002-1011, 2010
6) Trivedi MH, Rush AJ, Wisniewski SR et al : Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D : implications for clinical practice. Am J Psychiatry 163 : 28-40, 2006
7) Souery D, Oswald P, Massat I et al : Clinical factors associated with treatment resistance in major depressive disorder : results from a European multicenter study. J Clin Psychiatry 68 : 1062-1070, 2007
8) Fava M, Rush AJ, Alpert JE et al : Difference in treatment outcome in outpatients with anxious versus nonanxious depression : a STAR*D report. Am J Psychiatry 165 : 342-351, 2008
9) Dombrovski AY, Mulsant BH, Houck PR et al : Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord 103 : 77-82, 2007
10) Dunlop BW, Davis PG : Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression : a review. Prim Care Companion J Clin Psychiatry 10 : 222-228, 2008
11) Schoevers RA, Van HL, Koppelmans V et al : Managing the patient with co-morbid depression and an anxiety disorder. Drugs 68 : 1621-1634, 2008
12) Zimmerman M, Chelminski I : Clinician recognition of anxiety disorders in depressed outpatients. J Psychiatr Res 37 : 325-333, 2003
13) Sheehan DV, Lecrubier Y, Sheehan KH et al : The Mini-International Neuropsychiatric Interview (M. I. N. I.) : the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20) : 22-33, 1998 (大坪天平, 宮岡等, 上島国利訳 : M. I. N. I. 精神疾患簡易構造化面接法. 星和書店, 東京, 2000)
14) 朝倉聡, 井上誠士郎, 佐々木史ほか : Liebowitz Social Anxiety Scale (LSAS) 日本語版の信頼性及び妥当性の検討. 精神医学 44 : 1077-1084, 2002
15) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). APA, Arington, 2013 (高橋三郎, 大野裕監訳 : DSM-5 精神疾患の診断・統計マニュアル. 医学書院. 東京, 2014)
16) Bandelow B, Sher L, Bunevicius R et al : Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16 : 77-84, 2012
17) Sanchez C, Reines EH, Montgomery SA : A comparative review of escitalopram, paroxetine, and sertraline : Are they all alike? Int Clin Psychopharmacol 29 : 185-196, 2014
18) Schaffer A, McIntosh D, Goldstein BI et al : The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry 24 : 6-22, 2012
19) American Psychiatric Association : Practice guideline for the treatment of patients major depressive disorder, third edition (DSM-3), APA, Arlington, VA, 2010
20) 塩入俊樹, 桑原秀樹 : うつ病・急性期に併存する不安障害の薬物療法. 臨床精神薬理 17 : 1085-1095, 2014
21) Lenze EJ, Pollock BG, Shear MK et al : Treatment considerations for anxiety in the elderly. CNS Spectr 8 (Suppl 3) : 6-13, 2003
22) Rapaport MH : Prevalence, recognition, and treatment of comorbid depression and anxiety. J Clin Psychiatry 62 (Suppl 24) : 6-10, 2001
23) Lydiard RB, Brawman-Mintzer O : Anxious depression. J Clin Psychiatry 59 (Suppl 18) : 10-17, 1998
24) Laux G, Friede M, Muller WE : Treatment of comorbid anxiety and depression with escitalopram : results of a post-marketing surveillance study. Pharmacopsychiatry 46 : 16-22, 2013
P.125 掲載の参考文献
1) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, Third edition (DSM-III), APA, Wasington DC, 1980
2) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV), APA, Wasington DC, 1994
3) 日本精神神経学会 : 精神神経学用語集 改訂6版, 日本精神神経学会, 東京, 2008
4) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), APA, Arlington VA, 2013
5) 日本精神神経学会 : DSM-5 精神疾患の診断・統計マニュアル, 医学書院, 東京, 2014
6) Liebowitz MR, Schneier F, Campeas R et al : Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 49 : 290-300, 1992
7) Davidson JR, Potts N, Richichi E et al : Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13 : 423-428, 1993
8) Gelernter CS, Uhde TW, Cimbolic P et al : Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 48 : 938-945, 1991
9) Asakura S, Tajirna O, Koyalna T : Fluvoxamine treatment of generalized social anxiety disorder in Japan : a randomized double-blind, placebo-controlled Study. Int J Neuropsychopharmacol 10 : 263-274, 2007
10) Stein MB, Fyer AJ, Davidson JR et al : Fluvoxamine treatment of social phobia (social anxiety disorder) : a double-blind, placebo-controlled study. Am J Psychiatry 156 : 756-760, 1999
11) van Vliet IM, den Boer JA, Westenberg HG : Psychopharmacological treatment of social phobia ; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 115 : 128-134, 1994
12) Liebowitz MR, Stein MB, Tancer M et al : A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63 : 66-74, 2002
13) Liebowitz MR, Gelenberg AJ, Munjack D : Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62 : 190-198, 2005
14) Stein MB, Liebowitz MR, Lydiard RB et al : Proxetine treatment of generalized social phobia (social anxiety disorder) : a randomized controlled trial. JAMA 280 : 708-713, 1998
15) Katzelnick DJ, Kobak KA, Greist JH et al : Sertraline for social phobia : a double-blind, placebo-controlled crossover study. Am J Psychiatry 152 : 1368-1371, 1995
16) Liebowitz MR, DeMartinis NA, Weihs K et al : Efficacy of sertraline in severe generalized social anxiety disorder : results of a double-blind, placebo-controlled study. J Clin Psychiatry 64 : 785-792, 2003
17) Van Ameringen MA, Lane RM, Walker JR et al : Sertraline treatment of generalized social phobia : a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158 : 275-281, 2001
18) Kasper S, Stein DJ, Loft H et al : Escitalopram in the treatment of social anxiety disorder : randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186 : 222-226, 2005
19) Lader M, Stender K, Burger V et al : Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder : randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19 : 241-248, 2004
20) Liebowitz MR, Mangano RM, Bradwejn J et al : A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66 : 238-247, 2005
21) Rickels K, Mangano R, Khan A : A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 24 : 488-496, 2004
22) Stein MB, Pollack MH, Bystritsky A et al : Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder : a 6-month randomized controlled trial.Psychopharmacology (Berl) 177 : 280-288, 2005
23) van der Linden GJ, Stein DJ, van Balkom AJ : The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia) : a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 15 (suppl 2) : S15-S24, 2000
24) Stein DJ, Stein MB, Pitts CD et al : Predictors of response to pharmacotherapy in social anxiety disorder : an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 63 : 152-155, 2002
25) 朝倉聡, 筒井末春, 小山司 : Paroxetine塩酸塩水和物の社会不安障害に対する臨床評価-プラセボを対照とした二重亡検比較試験-. 臨床精神医学 37 : 833-848, 2008
26) Stein DJ, Versiani M, Hair T et al : Efficacy of paroxetine for relapse prevention in social anxiety disorder : a 24-week study. Arch Gen Psychiatry 59 : 1111-1118, 2002
27) Walker JR, Van Ameringen MA, Swinson R et al : Prevention of relapse in generalized social phobia : results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 20 : 636-644, 2000
28) Montgomery SA, Nil R, Durr-Pal N et al : A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66 : 1270-1278, 2005
29) Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 344 : 1279-1285, 2001
30) Wagner KD, Berard R, Stein MB et al : A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61 : 1153-1162, 2004
31) van Vliet IM, den Boer JA, Westenberg HG et al : Clinical effects of buspirone in social phobia : a double-blind placebo-controlled study. J Clin Psychiatry 58 : 164-168, 1997
32) Van Ameringen M, Mancini C, Wilson C : Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 39 : 115-121, 1996
33) Pande AC, Davidson JR, Jefferson JW et al : Treatment of social phobia with gabapentin : a placebo-controlled study. J Clin Psychopharmacol 19 : 341-348, 1999
34) Feltner DE, Liu-Dumaw M, Schweizer E et al : Efficacy of pregabalin in generalized social anxiety disorder : results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 26 : 213-220, 2011
35) Vaishnavi S, Alamy S, Zhang W et al : Quetiapine as monotherapy for social anxiety disorder : a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 31 : 1464-1469, 2007
36) Barnett SD, Kramer ML, Casat CD et al : Efficacy of olanzapine in social anxiety disorder : a pilot study. J Psychopharmacol 16 : 365-368, 2002
37) Stern RG, Petti TA, Bopp K et al : Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety : an open-label cross-taper study. J Clin Psychopharmacol 29 : 206-209, 2009
38) Tuccori M, Testi A, Antonioli L et al : Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy : a review. Clin Ther 31 : 1426-1453, 2009
39) Stein DJ, Andersen EW, Lader M : Escitalopram versus paroxetine for social anxiety disorder : An analysis of efficacy for different symptom dimensions. Eur Neuropsychopharmacol 16 : 33-38, 2006
40) Pelissolo A, Moukheiber A : Open-label treatment with escitalopram in patients with social anxiety disorder and fear of blushing. J Clin Psychopharmacol 33 : 695-698, 2013
P.131 掲載の参考文献
1) Dunner DL : The issue of comorbidity in the treatment of panic. Int Clin Psychopharmacol 13 (Suppl 4) : S19-S24, 1998
2) Goldberg DP : Anxious forms of depression. Depress Anxiety 31 : 344-351, 2014
3) Fava M, Rush AJ, Alpert JE et al : Difference in treatment outcome in outpatients with anxious versus nonanxious depression : a STAR*D report. Am J Psychiatry 165 : 342-351, 2008
4) Laux G, Friede M, Muller WE : Treatment of comorbid anxiety and depression with escitalopram : results of a post-marketing surveillance study. Pharmacopsychiatry 46 : 16-22, 2013
5) Lepola U, Arato M, Zhu Y et al : Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 64 : 654-662, 2003
6) 貝谷久宣 : 「非定型うつ病」の診断はなぜ使われないのか. 非定型うつ病, 日本評論社, 東京, 2008, pp.21-56
7) 貝谷久宣 : パニック性不安うつ病-不安-抑うつ発作を主徴とするうつ病. 心療内科 12 : 30-37, 2008
8) 貝谷久宣 : 不安・抑うつ発作Anxious-Depressive Fit-不安障害から気分障害への架け橋intermediary, mediator, pass way, tragetry症状. 精神科 13 : 302-309, 2008
9) 貝谷久宣 : 『押さえておきたい! 心身医学臨床の知』 "不安・抑うつ発作" を見逃さない. 心身医学 49 : 1017-1022, 2009
10) 貝谷久宣 : 「不安と抑うつ」再考. 臨床精神医学 39 : 403-409, 2010
11) 貝谷久宣 : 不安うつ病. 内科 105 : 275-279, 2010
12) 貝谷久宣 : 「展望」非定型うつ病-不安障害との併発をめぐって-. 精神医学 52 : 840-852, 2010
13) 貝谷久宣 : 不安・抑うつ症候群. 分子精神医学 50 : 84-88, 2013
14) 貝谷久宣 : パニック障害 ≪精神科臨床エキスパート≫ 不安障害診療のすべて. 医学書院, 東京, 2013, pp.121-164
15) 貝谷久宣, 土田英人 : 不安障害に併存するうつ病の特徴. デュロキセチンのすべて, 先端医学社, 東京, 2015, pp.178-185
16) Iketani T, Kiriike N, Stein MB et al : Personality disorder comorbidity in panic disorder patients with or without current major depression. Depress Anxiety 15 : 176-182, 2002
17) 貝谷久宣 : 神経科精神科・古参医の戯言 第11回「不 安・抑うつ発作」発見の歴史 (8) パニック障害における前頭葉機能低下の神経科学的背景. 精神療法 41 : 155-122, 2015
P.137 掲載の参考文献
1) Freeman MP, Freeman SA, McElroy SL : The comorbidity of bipolar and anxiety disorders : prevalence, psychobiology, and treatment issues. J Affect Disord 68 : 1-23, 2002
2) Latalova K, Prasko J, Grambal A et al : Bipolar disorder and anxiety disorders. Neuro Endocrinol Lett 34 : 738-744, 2013
3) Vazquez GH, Baldessarini RJ, Tondo L : Co-occurrence of anxiety and bipolar disorders : clinical and therapeutic overview. Depress Anxiety 31 : 196-206, 2014
4) Passmore MJ, Garnham J, Duffy A et al : Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord 5 : 110-114, 2003
5) Maina G, Albert U, Rosso G et al : Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity : a randomized, single-blind, pilot study. J Clin Psychiatry 69 : 609-616, 2008
6) Sheehan DV, Harnett-Sheehan K, Hidalgo RB et al : Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord 145 : 83-94, 2013
7) Perugi G, Frare F, Toni C et al : Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants : a 3-year "open" follow-up study. Eur Arch Psychiatry Clin Neurosci 260 : 553-560, 2010
8) Hirschfeld RM, Weisler RH, Raines SR et al : Quetiapine in the treatment of anxiety in patients with bipolar I or II depression : a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67 : 355-362, 2006
9) Uguz F : Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder. Gen Hosp Psychiatry 32 : 556-558, 2010
10) Sheehan DV, McElroy SL, Harnett-Sheehan K et al : Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord 115 : 376-385, 2009
P.140 掲載の参考文献
1) Hankin CS, Spiro A 3rd, Miller DR et al : Mental disorders and mental health treatment among U. S. Department of Veterans Affairs outpatients : the Veterans Health Study. Am J Psychiatry 156 : 1924-1930, 1999
2) Shore JH, Vollmer WM, Tatum EL : Community patterns of posttraumatic stress disorders. J Nerv Ment Dis 177 : 681-685, 1989
3) Gros DF, Price M, Magruder KM et al : Symptom overlap in posttraumatic stress disorder and major depression. Psychiatry Res 196 : 267-270, 2012
4) Trivedi MH, Rush AJ, Wisniewski SR et al : Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D : implications for clinical practice. Am J Psychiatry 163 : 28-40, 2006
5) Friedman ES, Wisniewski SR, Gilmer W et al : Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram : results of the NIMH STAR*D trial. Depress Anxiety 26 : 612-621, 2009
6) Jakubovski E, Bloch MH : Prognostic subgroups for citalopram response in the STAR*D trial. J Clin Psychiatry 75 : 738-747, 2014
7) Shalev AY, Ankri Y, Israeli-Shalev Y et al : Prevention of posttraumatic stress disorder by early treatment : results from the Jerusalem Trauma Outreach And Prevention study. Arch Gen Psychiatry 69 : 166-176, 2012
8) Robert S, Hamner MB, Ulmer HG et al : Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry 67 : 1522-1526, 2006
9) Hensley PL, Slonimski CK Uhlenhuth EH et al : Escitalopram : an open-label study of bereavement-related depression and grief. J Affect Disord 113 : 142-149, 2009
10) 日本トラウマティック・ストレス学会. PTSDの薬物療法ガイドライン : プライマリケア医のために 第1版, 2013 (http://www.jstss.org)
P.145 掲載の参考文献
1) Kendal RE, DiScipio WJ : Obsessional symptoms and obsessional personality traits in patients with depressive illness. Psychol Med 1 : 65-72, 1970
2) 松井徳造, 松永寿人, 岩崎陽J子ほか : 研究と報告 強迫性障害患者における大うつ病のcomorbidityと治療反応性への影響. 精神医学 43 : 957-962, 2001
3) 松永寿人 : 強迫性障害とうつ病-OCDのcomorbidityの観点から. 日本臨牀 38 : 455-458, 2003
4) Quarantini LC, Torres AR, Samnpaio AS et al : Comorbid major depression in obsessive-compulsive disorder patients. Compr Psychiatry 52 : 386-393, 2011
5) Regier DA, Rae DS, Narrow WE et al : Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry 173 : 24-28, 1998
6) Stein DJ : Psychobiology of anxiety disorders and obsessive-compulsive spectrum disorders. CNS Spectr 13 (suppl 14) : 23-28, 2008
7) Besiroglu L, Uguz F, Saglam M et al : Factors associated with major depressive disorder occurring after the onset of obsessive-compulsive disorder. J Affect Disord 102 : 73-79, 2007
8) Diniz JB, Rosario-Campos MC, Shavitt RG et al : Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder. J Clin Psychiatry 65 : 22-27, 2004
9) Fineberg NA, Fourie H, Gale TM et al : Comorbid depression in obsessive compulsive disorder (OCD) : symptomatic differences to major depressive disorder. J Affect Disord 87 : 327-330, 2005
10) Saxena S, Brody AL, Ho ML et al : Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biol Psychiatry 50 : 159-170, 2001
11) Saxena S, Brody AL, Ho ML et al : Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 59 : 250-261, 2002
12) Cardoner N, Soriano-Mas C, Pujol J et al : Brain structural correlates of depressive comorbidity in obsessive-compulsive disorder. Neuroimage 38 : 413-421, 2007
13) Yap K, Mogan C, Kyrios M : Obsessive-compulsive disorder and comorbid depression : The role of OCD-related and non-specific factors. J Anxiety Disord 26 : 565-573, 2012
14) Kamath P, Reddy YC, Kandavel T : Suicidal behavior in bsessive-compulsive disorder. J Clin Psychiatry 68 : 1741-1750, 2007
15) Torres AR, de Abreu Ramos-Cerqueira AT, Torresan RC et al : Prevalence and associated factors for suicidal ideation and behaviors in obsessive-compulsive disorder. CNS Spectr 12 : 771-778, 2007
16) Apter A, Horesh N, Gothelf D et al : Depression and suicidal behavior in adolescent inpatients with obsessive compulsive disorder. J Affect Disord 75 : 181-189, 2003
17) Keeley ML, Storch EA, Merlo LJ et al : Clinical predictors of response to cognitive-behavioral therapy for obsessive-compulsive disorder. Clin Psychol Rev 28 : 118-130, 2008
18) Koran LM, Hanna GL, Hollander E et al : Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 164 (suppl) : 5-53, 2007
19) 松永寿人 : 強迫性障害. 「神経症性障害の治療ガイドライン」精神科治療学 26 : 56-67, 2011
20) Dhillon S, Scott LJ, Plosker GL : Escitalopram : a review of its use in the management of anxiety disorders. CNS Drugs 20 : 763-790, 2006
21) Fineberg NA, Tonnoir B, Lemming O et al : Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 17 : 430-439, 2007
22) Stein DJ, Andersen EW, Tonnoir B et al : Escitalopram in obsessive-compulsive disorder : a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 23 : 701-711, 2007
23) Stein DJ, Carey PD, Lochner C et al : Escitalopram in obsessive-compulsive disorder : response of symptom dimensions to pharmacotherapy. CNS Spectr 13 : 492-498, 2008
24) Dougherty DD, Jameson M, Deckersbach T et al : Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 24 : 306-311, 2009
25) Rabinowitz I, Baruch Y, Barak Y : High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 23 : 49-53, 2008
26) Stein DJ, Koen N, Fineberg N et al : A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep 14 : 211-219, 2012
27) Valerio C, Diniz JB, Fossaluza V et al : Does anti-obsessional pharmacotherapy treat so-called comorbid depressive and anxiety states? J Affect Disord 139 : 187-192, 2012
28) Mancini C, Van Ameringen M, Farvolden P : Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder? J Affect Disord 68 : 59-65, 2002
29) Matsunaga H, Hayashida K, Maebayashi K et al : A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Int J Psychiatry Clin Pract 15 : 263-269, 2011

PART 5 エスシタロプラムによる治療の実際をみる

P.151 掲載の参考文献
1) Bertolote JM, Fleischmann A : Suicide and psychiatric diagnosis : a worldwide perspective. World Psychiatry 1 : 181-185, 2002
2) Nock MK Hwang I, Sampson N et al : Cross-national analysis of the associations among mental disorders and suicidal behavior : findings from the WHO World Mental Health Surveys. PLoS Med 6 : e1000123, 2009
3) Nordentoft M, Mortensen PB. Pedersen CB : Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry 68 : 1058-1064, 2011
4) Gusmao R, Quintao S, McDaid D et al : Antidepressant Utilization and Suicide in Europe : An Ecological Multi-National Study. PLoS One 8 : e66455, 2013
5) Teicher MH, Glod C, Cole JO : Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147 : 207-210, 1990
6) Stone M, Laughren T, Jones ML et al : Risk of suicidality in clinical trials of antidepressants in adults : analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339 : b2880, 2009
7) Healy D : Let them eat prozac : the unhealthy relationship between the pharmaceutical industry and depression (medicine, culture, and history), NYU press, New York, 2006 (川島治監修, 谷垣暁美訳 : 抗うつ薬の功罪. みすず書房, 東京, 2005)
8) Coupland C, Hill T, Morriss R et al : Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64 : cohort study using a primary care database. BMJ 150 : h517, 2015
9) Soutullo C, Figueroa-Quintana A : When do you prescribe antidepressants to depressed children? Curr Psychiatry Rep 15 : 366, 2013
10) Sullivan GM, Oquendo MA, Milak M et al : Positron emission tomography quantification of serotonin1A receptor binding in suicide attempters with major depressive disorder. JAMA Psychiatry 72 : 169-78, 2015
11) Bach H, Huang YY, Underwood MD et al : Elevated serotonin and 5-HIAA in the brainstem and lower serotonin turnover in the prefrontal cortex of suicides. Synapse 68 : 127-130, 2014
12) Bech P, Tanghoj P, Cialdella P et al : Escitalopram dose-response revisited : an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 7 : 283-290, 2004
13) Pedersen AG : Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol 20 : 139-143, 2005
14) Perroud N, Uher R, Marusic A et al : Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP) : a clinical trial. BMC Med 7 : 60, 2009
15) Davis A, Gilhooley M, Agius M et al : Suicide risk and choice of antidepressant. Psychiatr Danub 22 : 358-359, 2010
16) Pandey GN Dwivedi Y : Noradrenergic function in suicide. Arch Suicide Res 11 : 235-246, 2007
17) Gonzalez-Maeso J, Rodriguez-Puertas R, Meana JJ et al : Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders : selective supersensitivity of α2A-adrenoceptors. Mol Psychiatry 7 : 755-767, 2002
18) Ryding E, Lindstrom M, Traskman-Bendz L : The role of dopamine and serotonin in suicidal behaviour and aggression. Prog Brain Res 172 : 307-315, 2008
19) Agren H, Mefford IN, Rudorfer MV et al : Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiatr Res 20 : 175-193, 1986
20) McGirr A, Renaud J, Seguin M et al : An examination of DSM-IV depressive symptoms and risk for suicide completion in major depressive disorder : a psychological autopsy study. J Affect Disord 97 : 203-209, 2007
21) Wasserman D, Rihmer Z, Rujescu D et al : The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry 27 : 129-141, 2012
22) Juurlink DN, Mamdani MM, Kopp A et al : The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163 : 813-821, 2006
23) Mann JJ, Apter A, Bertolote J et al : Suicide prevention strategies : a systematic review. JAMA 294 : 2064-2074, 2005
P.155 掲載の参考文献
1) Biederman J, Newcorn J, Sprich S : Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148 : 564-577, 1991
2) Stringaris A, Cohen P, Pine DS et al : Adult outcomes of youth irritability : a 20-year prospective community-based study. Am J Psychiatry 166 : 1048-1054, 2009
3) Hazell P, O'Connell D, Heathcote D et al : Efficacy of tricyclic drugs in treating child and adolescent depression : a meta-analysis. BMJ 310 : 897-901, 1995
4) March JS, Silva S, Petrycki S et al : The Treatment for Adolescents With Depression Study (TADS) : long-term effectiveness and safety outcomes. Arch Gen Psychiatry 64 : 1132-1143, 2007
5) National Institute for Health and Clinical Excellence : Depression in children and young people : Identification and management in primary, community and secondary care, 2013 (http://www.nice.org.uk/Guidance/cg28)
6) Emslie GJ, Ventura D, Korotzer A et al : Escitalopram in the treatment of adolescent depression : a randomized placebo-controlled multisite trial. J Am Aca Child Adolesc Psychiatry 48 : 721-729, 2009
7) Wagner KD, Jonas J, Findling RL et al : A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45 : 280-288, 2006
P.162 掲載の参考文献
1) Hickie I, Scott E, Mitchell P et al : Subcortical hyperintensities on magnetic resonance imaging : Clinical correlates and prognostic significance in patients with severe depression, Biol Psychiatry 37 : 151-160, 1995
2) Henn FA, Vollmayr B et al : Neurogenesis and depression : etiology or epiphenomenon? Biol Psychiatry 56 : 146-150, 2004
3) 渡邊尚志, 今西泰一郎, 角井信一ほか : ミルタザピンの薬理プロファイル-αアドレナリン受容体モデルによる結合様式の観点から-, 新薬と臨牀 58 : 1152-1160, 2009
4) Sanchez C, Bergqvist PB, Brennurn LT et al : Escitalopram, the S-+ -enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 167 : 353-362, 2003
5) CANMAT : CAMMAT Depression Guidelines. (http://www.canmat.org/guides.php)
6) Gorwood P, Weiller E, Lemming O et al : Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 15 : 581-593, 2007
7) Kasper S, Lemming OM, de Swart H : Escitalopram in the long-term treatment of major depressive disorder in elderly patients. Neuropsychobiology 54 : 152-159, 2006
8) Mohamed S, Osatuke K, Aslam M et al : Escitalopram for comorbid depression and anxiety in elderly patients : A 12-week, open-label, flexible-dose, pilot trial. Am J Geriatr Pharmacother 4 : 201-209, 2006
9) 平安良雄 : Escitalopramの大うつ病性障害患者を対象とした長期投与試験. 臨床精神薬理 14 : 901-912, 2011
10) 平安良雄 : Escitalopramの高齢の大うつ病性障害患者を対象とした長期投与試験, 臨床精神薬理 14 : 913-923, 2011
11) 医薬品インタビューフォーム (レクサプロ(R) 錠 10mg) 2013年6月改訂 (第4版) (http://medical.mt-pharma.cojp/di/file/if/f_lex.pdf)
12) 木村真人 : 話題のくすり エスシタロプラムシュウ酸塩. 日病薬誌 48 : 371-375, 2012
P.168 掲載の参考文献
1) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), APA, Arlington, 2013 (高橋二郎, 大野裕監訳 : DSM-5 精神疾患の診断・統計マニュアル. 医学書院, 東京, 2014)
2) Nelson HD : Menopause. Lancet 371 : 760-770, 2008
3) 山田和男 : 更年期障害に対する精神科薬物療法. 精神科治療学 28 : 929-934, 2013
4) Parry BL : Perimenopausal depression. Am J Psychiatry 165 : 23-27, 2008
5) Cohen LS, Soares CN, Vitonis AF et al : Risk for new onset of depression during the menopausal transition : the Harvard study of moods and cycles. Arch Gen Psychiatry 63 : 385-390, 2006
6) 山田和男, 井上由美子, 原田豪人 : エビデンスに基づいた更年期うつ病の薬物治療ガイドライン, 難治性気分障害の治療-エビデンスレビュー 2013, 神庭重信編, アークメディア, 東京, 2013, pp.142-148
7) 山田和男 : 性ホルモンと気分障害関連障害 (更年期障害を含む). 臨床精神医学 27 : 1105-1112, 1998
8) 山田和男訳 : WFSBP (生物学的精神医学会世界連合) 版単極性うつ病の生物学的治療ガイドライン 第1部 大うつ病性障害の急性期と継続期の治療 2013年改訂版, 星和書店, 東京, 2014
9) 山田和男 : 月経前不快気分障害. 女性医療とメンタルケア, 創造出版, 東京, 2012, pp.34-46
10) Eriksson E, Ekman A, Sinclair S et al : Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol 28 : 195-202, 2008
11) 山田和男, 神庭重信 : エビデンスに基づいた月経前不快気分障害 (PMDD) の薬物治療ガイドライン 2013年 改訂版. 難治性気分障害の治療 : エビデンスレビュー 2013. アークメディア, 東京, 2013, pp.130-141
P.172 掲載の参考文献
1) 三木治 : プライマリ・ケアにおけるうつ病の実態と治療. 心身医学 42 : 585-591, 2002
2) Bell RA, Franks P, Duberstein PR et al : Suffering in silence : Reasons for not disclosing depression in primary care. Ann Fam Med 9 : 439-446, 2011
3) 厚生労働省 : 平成25年国民健康・栄養調査報告, 2013 (http://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h25-houkoku.pdf)
4) Anderson RJ, Freedland KE, Clouse RE et al : The prevalence of comorbid depression in adults with diabetes : a meta-analvsis. Diabetes Care 24 : 1069-1078, 2001
5) Knol MJ, Twisk JW, Beekman AT et al : Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 49 : 837-845, 2006
6) Richardson LK, Egede LE, Mueller M et al : Longitudinal effects of depression on glycemic control in veterans with Type 2 diabetes. Gen Hosp Psychiatry 30 : 509-514, 2008
7) Gehlawat P, Gupta R, Rajput R et al : Diabetes with comorbid depression : role of SSRI in better glycemic control. Asian J Psychiatr 6 : 364-368, 2013
8) Dimsdale JE : Psychological stress and cardiovascular disease. J Am Coll Cardiol 51 : 1237-1246, 2008
9) Jiang W, Velazquez EJ, Kuchibhatla M et al : Effect of escitalopram on mental stress-induced myocardial ischemia : results of the REMIT trial. JAMA 309 : 2139-2149, 2013
10) Ayerbe L, Ayis S, Wolfe CD et al : Natural history, predictors and outcomes of depression after stroke : systematic review and meta-analysis. Br J Psychiatry 202 : 14-21, 2013
11) Robinson RG, Jorge RE, Moser DJ et al : Escitalopram and problem-solving therapy for prevention of poststroke depression : a randomized controlled trial. JAMA 299 : 2391-2400, 2008
12) Mikami K, Jorge RE, Moser DJ et al : Increased frequency of first-episode poststroke depression after discontinuation of escitalopram. Stroke 42 : 3281-3283, 2011
13) Freeman EW, Guthrie KA, Caan B et al : Efficacy of escitalopram for hot flashes in healthy menopausal women : a randomized controlled trial. JAMA 305 : 267-274, 2011
14) Berendsen HH : The role of serotonin in hot flushes. Maturitas 36 : 155-164, 2000
15) Leutscher PD, Lagging M Buhl MR et al : Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 52 : 430-435, 2010
16) Schaefer M, Sarkar R, Knop V et al : Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease : a randomized trial. Ann Intern Med 157 : 94-103, 2012
18) Baldwin DS, Montgomery SA, Nil R et al : Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10 : 73-84, 2007
19) Sanchez C, Reines EH, Montgomery SA : A comparative review of escitalopram, paroxetine, and sertraline : Are they all alike? Int Clin Psychopharmacol 29 : 185-196, 2014
20) Castro VM, Clements CC, Murphy SN et al : QT interval and antidepressant use : a cross sectional study of electronic health records. BMJ 29 : 346, 2013
P.178 掲載の参考文献
1) Salomon JA, Vos T, Hogan DR et al : Common values in assessing health outcomes from disease and injury : disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380 : 2129-2143, 2012
2) 厚生労働省. 平成24年度労働者健康状況調査, 2012
3) Furukawa TA, Takeuchi H, Hiroe T et al : Symptomatic recovery and social functioning in major depression. Acta Psychiatr Scand 103 : 257-261, 2001
4) Collins JJ, Baase CM, Sharda CE et al : The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med 47 : 547-557, 2005
5) Stewart WF, Ricci JA, Chee E et al : Cost of lost productive work time among US workers with depression. JAMA 289 : 3135-3144, 2003
6) Tollefson GD, Souetre E, Thomander L et al : Comorbid anxious signs and symptoms in major depression : impact on functional work capacity and comparative treatment outcomes. Int Clin Psychopharmacol 8 : 281-293, 1993
7) Souetre E, Lozet H, Cimarosti I et al : Predicting factors for absenteeism in patients with major depressive disorders. Eur J Epidemiol 13 : 87-93, 1997
8) Sackeim HA, Kupfer DJ, Luther J et al : Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report. Am J Psychiatry 163 : 1905-1917, 2006
9) Olfson M, Marcus SC, Tedeschi M et al : Continuity of antidepressant treatment for adults with depression in the united states. Am J Psychiatry 163 : 101-108, 2006
10) Bambauer KZ, Adams AS, Zhang F et al : Physician alerts to increase antidepressant adherence. Fax or fiction? Arch Intern Med 166 : 498-504, 2006
11) Yoshimura R, Ikenouchi-Sugita A, Umene-Nakano W et al : Nonadherence to paroxetine : a study based on monitoring plasma paroxetine levels. J Clin Psychopharmacol 30 : 82-83. 2010
12) 渡邊衡一郎, 菊池俊暁 : 抗うつ薬服用者を対象としたウェブ調査2008の結果に見る患者の気持ち. 臨床精神薬理 12 : 2295-2304, 2008
13) Prien RF, Kupfer DJ : Continuation drug therapy for major depressive episodes : how long should it be maintained? Am J Psychiatry 143 : 18-23, 1986
14) Geddes JR, Carney SM, Davies C et al : Relapse prevention with antidepressant drug treatment in depressive disorders : a systematic review. Lancet 361 : 653-661, 2003
15) Sogaard B, Mengel H, Rao N et al : The pharmacokinetics of escitalopram after oral and intravenous administration of single and muitiple doses to healthy subjects. J Clin Pharmacol 45 : 1400-1406, 2005
16) Soczynska JK, Ravindran LN, Styra R et al : The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder : results from a randomized controlled trial. Psychiatry Res 220 : 245-250, 2014
P.185 掲載の参考文献
1) 川上憲人 : こころの健康についての疫学調査に関する研究. 平成18年度厚生労働科学研究費補助金 (こころの健康科学研究事業) 総括研究報告書, 2006
3) Kennedy SH, Andersen HF, Thase ME : Escitalopram in the treatment of major depressive disorder : a meta-analysis. Curr Med Res Opin 25 : 161-175, 2009
4) 持田製薬 : レクサプロ錠10mg添付文書 (第4版), 2015 (http://database.japic.or.jp/pdf/newPINS/00059702.pdf)
5) 平安良雄 : Escitalopramの大うつ病性障害患者を対象とした用量反応・非劣性試験による有効性と安全性の検証-プラセボおよびparoxetineを対照とした二重盲検比較試験-. 臨床精神薬理 14 : 883-899, 2011
6) Wade A, Gembert K, Florea I : A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 23 : 1605-1614, 2007
7) Baldwin DS, Reines EH, Guiton C et al : Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 41 : 1583-1592, 2007
8) Wade A, Michael Lernming O, Bang Hedegaard K : Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17 : 95-102, 2002
9) 佐藤宏宣, 平安良雄 : Escitalopram臨床薬物動態試験-単回投与および反復投与試験 (英国) -. 臨床精神薬理 14 : 857-870, 2011
10) Klein N, Sacher J, Geiss-Granadia T et al : Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram : an 123I ADAM SPECT study. Psychopharmacology (Berl) 191 : 333-339, 2007
11) Baldwin DS, Cooper JA, Huusom AK et al : A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 21 : 159-169, 2006
12) Spina E, Trifiro G, Caraci F : Clinically significant drug interactions with newer antidepressants. CNS Drugs 26 : 39-67, 2012
13) Pedersen AG : Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol 20 : 139-143, 2005
14) 宮岡等 : Escitalopram・QT延長症候群・意識消失. 精神治療学 27 : 1502-1504, 2012
15) Marcus SC, Hassan M, Olfson M : Antidepressant switching among adherent patients treated for depression. Psychiatr Serv 60 : 617-623, 2009
16) David Taylor, Carol Paton, Shitij Kapur : The Maudsley Prescribing Guidelines in Psychiatry 11th edition. 『モーズレイ処方ガイドライン 第11版』ワイリー・パブリッシング・ジャパン, 2013
17) Perahia DG, Quail D, Desaiah D et al : Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants : a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 69 : 95-105, 2008
P.188 掲載の参考文献
1) 厚生労働省 : 労働安全衛生法に基づくストレスチェック制度実施マニュアル. 2015 (http://www.mhlw.go.jp/bunya/roudoukijun/anzeneisei12/pdf/150507-1.pdf)
2) 厚生労働省 : 心理的な負担の程度を把握するための検査及び面接指導の実施並びに面接指導結果に基づき事業者が講ずべき措置に関する指針. 2015 (http://www.mhlw.go.jp/file/04-Houdouhappyou-11201250-Roudoukijunkyoku-Roudoujoukenseisakuka/0000082591.pdf)
3) 佐渡充洋 : 精神医学のフロンティア うつ病による社会的損失はどの程度になるのか? : うつ病の疾病費用研究. 精神神経学雑誌 116 : 107-115, 2014
4) 厚生労働省 : 心の健康問題により休業した労働者の職場復帰支援の手引き. 2009 (http://www.mhlw.go.jp/new-info/kobetu/roudou/gyousei/anzen/dl/101004-1.pdf)
5) Lam RW, Michalak EE, Bond DJ et al : Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? Depress Res Treat 2012 : 630206, 2012
6) Lam RW, Kennedy SH, Grigoriadis S et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 117 (Suppl 1) : S26-S43, 2009
7) Nierenberg AA, Husain MM, Trivedi MH et al : Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse : a STAR*D report. Psychol Med 40 : 41-50, 2010
8) Akerblad AC, Berlgtsson F, von Knorring L et al : Response, remission and relapse in relation to adherence in primary care treatment of depression : a 2-year outcome study. Int Clin Psychopharmacol 21 : 117-124, 2006
9) Hung CI : Factors predicting adherence to antidepressant treatment. Curr Opin Psychiatry 27 : 344-349, 2014
10) Gartlehner G, Hansen RA, Morgan LC et al : Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder : an updated meta-analysis. Ann Intern Med 155 : 772-785, 2011
11) Nieuwenhuijsen K, Faber B, Verbeek JH et al : Interventions to improve return to work in depressed people. Cochrane Databasse Syst Rev 12 : CD006237, 2014
12) Wade AG, Fernandez JL, Francois C et al : Escitalopram and duloxetine in major depressive disorder : a pharmacoeconornic comparison using UK cost data. Pharmacoeconomics 26 : 969-981, 2008
13) Fantino B, Moore N, Verdoux H et al : Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int Clin Psychopharmacol 22 : 107-115, 2007
14) Papakostas GI : Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. J Clin Psychiatry 75 : 8-14, 2014
15) Keefe RS, McClintock SM, Roth RM et al : Cognitive effects of pharmacotherapy for major depressive disorder : a systematic review. J Clin Psychiatry 75 : 864-876, 2014
16) Nagane A, Baba H, Nakano Y et al : Comparative study of cognitive impairment between medicated and medication-free patients with remitted major depression : class-specific influence by tricyclic antidepressants and newer antidepressants. Psychiatry Res 218 : 101-105, 2014
17) Wingen M, Bothmer J, Langer S et al : Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo : a crossover trial. J Clin Psychiatry 66 : 436-443, 2005
18) 日本精神神経学会 : 患者の自動車連転に関する精神科医のためのガイドライン. 2014 (https://www.jspn.or.jp/uploads/uploads/files/activity/20140625_guideline.pdf)
19) Hollon SD, DeRubeis RJ, Fawcett J et al : Effect of cognitive therapy with antidepressant rnedications vs antidepressants alone on the rate of recovery in major depressive disorder : a randomized clinical trial. JAMA Psychiatry 71 : 1157-1164, 2014
20) Lam RW, Parikh SV, Ramasubbu R et al : Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. Br J Psychiatry 203 : 358-365, 2013
21) Tan L, Wang MJ, Modini M et al : Preventing the development of depression at work : a systematic review and meta-analysis of universal interventions in the workplace. BMC Med 12 : 74, 2014

PART 6 エスシタロプラムの安全性からみた臨床応用

P.196 掲載の参考文献
1) 日本臨床精神神経薬理学会専門医制度委員会 : 臨床精神神経薬理学テキスト 改訂第3版, 星和書店, 東京, 2014, pp.208-226
2) Westenberg HG, Sandner C : Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 60 : 482-491, 2006
3) 気分障害の治療ガイドライン作成委員会 : II. 大うつ病性障害 2012 Ver.1, 日本うつ病学会治療ガイドライン, 2013
4) Gartlehner G, Hansen RA, Morgan LC et al : Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder : an updated meta-analysis. Ann Intern Med 155 : 772-785, 2011
5) Demyttenaere K, Jaspers L : Review : Bupropion and SSRI-induced side effects. J Psychopharmacol 22 : 792-804, 2008
6) Simon GE, Savarino J, Operskalski B et al : Suicide risk during antidepressant treatment. Am J Psychiatry 163 : 41-47, 2006
8) Haddad P : The SSRI discontinuation syndrome. J psychopharmacol 12 : 305-313, 1998
9) Schatzberg AF, Blier P, Delgado PL et al : Antidepressant discontinuation syndrome : consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 67 (Suppl 4) : 27-30, 2006
10) Andrade C, Sandarsh S, Chethan KB et al : Serotonin reuptake inhibitor antidepressants and abnormal bleeding : a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 71 : 1565-1575, 2010
11) Rottmann CN : SSRIs and the syndrome of inappropriate antidiuretic hormone secretion. Am. J Nurs 107 : 51-58, 2007
12) Haddad PM, Dursun SM : Neurological complications of psychiatric drugs : clinical features and management. Hum Psychopharmacol 23 (Suppl 1) : 15-26, 2008
13) Owens MJ, Knight DL, Nemeroff CB : Second-generation SSRIs : human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50 : 345-350, 2001
14) Waugh J, Goa KL : Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 17 : 343-362, 2003
15) Sanchezc, Reines EH, Montgomery SA : A comparative review of escitalopram, paroxetine, and sertraline : Are they all alike? Int Clin Psychopharmacol 29 : 185-196, 2014
16) Spina E, Santoro V, D'Arrigo C : Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants : an update. Clin Ther 30 : 1206-1227, 2008
17) Spina E, Trifiro G, Caraci F : Clinically significant drug interactions with newer antidepressants. CNS Drugs 26 : 39-67, 2012
18) Rao N : The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 46 : 281-290, 2007
19) 日本循環器学会, 日本心臓病学会, 日本心電学会ほか : QT延長症候群 (先天性・二次性) とBrugada症候群の診療に関するガイドライン 2007年改訂版, 2007 (http://www.j-circ.or.jp/guideline/pdf/JCS2007_ohe_h.pdf)
20) Castro VM, Clements CC, Murphy SN et al : QT interval and antidepressant use : a cross sectional study of electronic health records. BMJ 346 : f288, 2013
21) Beach SR, Celano CM, Noseworthy PA et al : QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 54 : 1-13, 2013
P.201 掲載の参考文献
1) 鈴木映二 : 薬物療法の適正化に向けて向精神薬の多剤処方と薬の相互作用. 臨床精神医学 42 : 169. -182, 2013
2) 持田製薬 : レクサプロインタビューフォーム 2013年6月改訂 (第4版) (http://medical.mt-pharma.co.jp/di/file/if/f_lex.pdf)
3) Hallberg P, Melhus H : Digitalis intoxication induced by paroxetine co-administration. Lancet 367 : 788, 2006
4) Canadian Network for Mood and Anxiety Treatments (CAMMAT), 2013 (http://www.canmat.org/guides.php)
5) 越前宏俊 : CYP2C19の遺伝子多型 : Clinician 503 : 88-93, 2001 (http://www.e-clinician.net/vol48/no503/pdf/tailor_503.pdf)
6) Spina E, Santoro V, D'Arrigo C : Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants : an update. Clin Ther 30 : 1206-1227, 2008
7) Jiang HY, Chen HZ, H XJ et al : Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding : a systematic review and meta-analysis. Clin Gastroenterol Hepatol 13 : 42-50, 2015
8) Lindqvist PG, Nasiell J, Gustafsson LL et al : Selective serotonin reuptake inhibitor use during pregnancy increases the risk of postpartum hemorrhage and anemia : a hospital-based cohort study. J Thromb Haemost 12 : 1986-1992, 2014
9) Masclee GM, Valkhoff VE, Coloma PM et al : Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 147 : 784-792, 2014
10) Anglin R, Yuan Y, Moayyedi P et al : Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use : a systematic review and meta-analysis. Am J Gastroenterol 109 : 811-819, 2014
11) 稲田健, 石郷岡純 : シンプル処方のすすめ. 臨床精神医学 43 : 5-10, 2014

PART 7 うつ病治療の今後とエスシタロプラムの役割

P.209 掲載の参考文献
1) Cipriani A, Furukawa TA, Salanti G et al : Comparative efficacy and acceptability of 12 new-generation antidepressants : a multiple-treatments Ineta-analysis. Lancet 373 : 746-758, 2009
2) Sanchez C, Reines EH, Montgomery SA : A comparative review of escitalopram, paroxetine, and sertraline : are they all alike? Int Clin Psychopharmacol 29 : 185-196, 2014
3) Kasper S, Spadone C, Verpillat P et al : Onset of action of escitalopram compared with other antidepressants : results of a pooled analysis. Int Clin Psychopharmacol 21 : 105-110, 2006
4) Gartlehner G, Hansen RA, Morgan LC et al : Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder : an updated meta-analysis. Ann Intern Med 155 : 772-785, 2011
5) Kirino E : Escitalopram for the management of major depressive disorder : a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence 6 : 853-861, 2012
6) Lam RW, Kennedy SH, Grigoriadis S et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 117 (Suppl 1) : S26-S43, 2009
7) Chen F, Larsen MB, Neubauer HA et al : Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 92 : 21-28, 2005
8) Wennogle LP, Meyerson LR : Serotonin uptake inhibitors differentially modulate high affinity imipramine dissociation in human platelet membranes. Life Sci 36 : 1541-1550, 1985
9) Mork A, Kreilgaard M, Sanchez C : The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45 : 167-173, 2003
10) Mansari MEL, Sanches C, Chouvet G et al : Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission : an in vivo electrophysiological study in rat brain. Neuropsychopharmacol 30 : 1269-1277, 2005
11) Blier P : possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 62 (suppl 4) : 7-11, 2001
12) Wade A, Friis Andersen H : The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 22 : 2101-2110, 2006
13) Mnie-Filali O, Mansari MEL, Sanchez C et al : Therapeutic relevance of the allosteric modulation of the 5-HT transporter. Curr Sig Trausduct Ther 4 : 82-87, 2009
14) Sawaguchi T, Goldman-Rakic PS : D1 dopamine receptors in prefrontal cortex : involvement in working memory. Science 251 : 947-950, 1991
15) Dunlop BW, Nemeroff CB : The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64 : 327-337, 2007
16) Fevissa AM, Chandran A, Stockmeier CA : Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 33 : 70-75, 2009
17) Chamberlain SR, Muller U, Blackwell AD et al : Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311 : 861-863, 2006
18) Schilstrom B, Konradsson-Geuken A, Ivanov V et al : Effects of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl-D-aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat. Synapse 65 : 357-367, 2011
19) Di Mascio M, Di Giovanni G, Di Matteo V et al : Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopalninergic neurons in the ventral tegmental area. Brain Res Bull 46 : 547-554, 1998
20) Couto FS, Batalha VL, Valadas JS et al : Escitalopram improves memory deficits induced by maternal separation in the rat. Eur J Pharmacol 695 : 71-75, 2012
21) Culang-Reinlieb ME, Sneed JR, Keilp JG et al : Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. Int J Geriatr Psychiatry 27 : 777-784, 2012
22) Soczynska JK, Ravindran LN, Styra R et al : The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder : results from a randomized controlled trial. Psychiatry Res 220 : 245-250, 2014
23) Culang ME, Sneed JR, Keilp JG et al : Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriatr Psychiatry 17 : 881-888, 2009
24) Jorge RE, Acion L, Moser D et al : Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 67 : 187-196, 2010
P.213 掲載の参考文献
1) Polyakova M, Stuke K, Schuemberg K et al : BDNF as a biolomarker for successful treatment of mood disorders : a systematic and quantative meta-analysis. J Affect Disord 174 : 432-440, 2015
2) Sen S, Duman R, Sanacora G : Serum brain-derived neurotrophic factor, depression, and antidepressant medications : meta-analyses and implications. Biol Psychiatry 64 : 527-532, 2008
3) Bocchio-Chiavetto L, Bagnardi V, Zanardini R et al : Serum and plasma BDNF levels in major depression : a replication study and meta-analyses. World J Biol Psychiatry 11 : 763-773, 2010
4) Lee BH, Park YM, Um TH et al : Lower serum brain-derived neurotrophic factor levels are associated with failure to achieve remission in patients with major depression after escitalopram treatment. Neuropsychiatr Dis Treat 10 : 1393-1398, 2014
5) Martocchia A, Curto M, Scaccianoce S et al : Effects of escitalopram on serum BDNF levels in elderly patients with depression : a preliminary report. Aging Clin Exp Res 24 : 461-464, 2014
6) El-Hage W, Vourc'h P, Gaillard P et al : The BDNF Val66Met polymorphism is associated with escitalopram response in depressed patients. Psychopharmacology (Berl) 232 : 575-581, 2015
7) Uher R, Perroud N, Ng MY et al : Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 167 : 555-564, 2010
8) Powell TR, Smith RG, Hackinger S et al : DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Transl Psychiatry 3 : e300, 2013
P.219 掲載の参考文献
1) Mitchell AJ, Chan M, Bhatti H et al : Prevalence of depression, anxiety. and adjustment disorder in oncological, haematological, and palliative-care settings : a meta-analysis of 94 interview-based studies. Lancet Oncol 12 : 160-174, 2011
2) 清水研 : II うつ病, 適応障害. 精神腫瘍学, 内富庸介, 小川朝生編, 医学書院, 東京, 2011, pp.96-107
3) 内富庸介 : 【各種疾患にみられる抑うつ状態の診断と治療】癌患者の抑うつと薬物治療. 臨床精神薬理 15 : 1135-1143, 2012
4) Hart SL, Hoyt MA, Diefenbach M et al : Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst 104 : 990-1004, 2012
5) Laoutidis ZG, Mathiak K : Antidepressants in the treatment of depression/depressive symptoms in cancer patients : a systematic review and meta-analysis. BMC Psychiatry 13 : 140, 2013
6) National Collaborating Centre for Mental Health Commissioned by the National Institute for Health and Clinical Excellence : Depressio in adults with a chronic physical health problem : treatment and management (NICE clinical guideline 91), 2010 (www.nice.org.uk/CG91)
7) Lydiatt WM, Bessette D, Schmid KK et al : Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer : randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol Head Neck Surg 139 : 678-686, 2013
8) Park HY, Lee BJ, Kim JH et al : Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer : a 12-week, open-label prospective trial. Progr Neuropsychopharmacol Biol Psychiatry 36 : 318-323, 2012
9) 輪湖哲也, 伊勢雄也, 片山志郎 : 【緩和医療の「困った」に答える】化学療法と緩和医療で使う薬剤の関係がわからない. 月刊薬事 51 : 629-635, 2009
10) De Vane CL, Pharm D, 富田顕旨訳 : 第7章 薬物動態学と薬力学の原則. 精神神経薬理学大事典, Schatzberg A, Nemeroff C編, 兼子直, 尾崎紀夫総監訳, 西村書店, 東京, 2012, pp.114-128
11) Schellander R, Donnerer J : Antidepressants : clinically relevant drug interactions to be considered. Pharmacology 86 : 203-215, 2010
12) Kelly CM, Juurlink DN, Gomes T et al : Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen : a population based cohort study. BMJ 340 : c693, 2010
13) Cronin-Fenton DP, Lash TL : Clinical epidemiology and pharmacology of CYP2D6 inhibition reiated to breast cancer outcomes. Expert Rev Clin Pharmacol 4 : 363-377, 2011
14) L'Esperance S, Frenette S, Dionne A et al : Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors : CEPO review and recommendations. Support Care Cancer 21 : 1461-1474, 2013
15) Lash TL, Pedersen L, Cronin-Fenton D et al : Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 99 : 616-621, 2008
16) Weiss J, Dormann SM, Martin-Facklam M et al : Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305 : 197-204, 2003
17) Lerner DM, Stoudemire A, Rosenstein DL : Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 40 : 428-435, 1999
18) Udina M, Hidalgo D, Navines R et al : Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C : a systematic review and meta-analysis. J Clin Psychiatry 75 : e1113-e1121, 2014
19) Musselman DL, Lawson DH, Gumnick JF et al : Paroxetine for the prevention of depression induced by high-dose interferon α. N Engl J Med 344 : 961-966, 2001
20) Musselman D, Royster EB, Wang M et al : The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma : preliminary findings. Neuropsychopharmacology 38 : 1921-1928, 2013
21) Freeman EW, Guthrie KA, Caan B et al : Efficacy of escitalopram for hot flashes in healthy menopausal women : a randomized controlled trial. JAMA 305 : 267-274, 2011
22) Dharmshaktu P, Tayal V, Kalra BS : Efficacy of antidepressants as analgesics : a review. J Clin Pharmacol 52 : 6-17, 2012
23) Tolia M, Fotineas A, Nikolaou K et al : Radiotherapy combined with daily escitalopram in patients with painful bone metastasis : clinical evaluation and quality of life measurements. J BUON 19 : 819-825, 2014
24) Jaracz J, Gattner K, Moczko J et al : Comparison of the effects of escitalopram and nortriptyline on painful symptoms in patients with major depression. Gen Hosp Psychiatry 37 : 36-39, 2015

最近チェックした商品履歴

Loading...